
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="152550808AF420D3055080000439EECE.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="ncomms">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365225/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Nature Communications">
<meta name="citation_title" content="Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma">
<meta name="citation_author" content="Amin H Nassar">
<meta name="citation_author_institution" content="Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA">
<meta name="citation_author" content="Chul Kim">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, Georgetown Cancer Institute, Washington, DC USA">
<meta name="citation_author" content="Tolulope Adeyelu">
<meta name="citation_author_institution" content="Caris Life Sciences, Phoenix, AZ USA">
<meta name="citation_author" content="Elias Bou Farhat">
<meta name="citation_author_institution" content="Division of Pulmonary Medicine, Brigham and Women’s Hospital, Boston, MA USA">
<meta name="citation_author" content="Hassan Abushukair">
<meta name="citation_author_institution" content="Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA">
<meta name="citation_author_institution" content="Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA">
<meta name="citation_author" content="Mehrdad Rakaee">
<meta name="citation_author_institution" content="Division of Pulmonary Medicine, Brigham and Women’s Hospital, Boston, MA USA">
<meta name="citation_author_institution" content="Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway">
<meta name="citation_author" content="Kelsey Matteson">
<meta name="citation_author_institution" content="Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA">
<meta name="citation_author" content="Shun-Fat Lau">
<meta name="citation_author_institution" content="Department of Immunobiology, Yale University, New Haven, CT USA">
<meta name="citation_author" content="Yamato Takabe">
<meta name="citation_author_institution" content="Department of Immunobiology, Yale University, New Haven, CT USA">
<meta name="citation_author" content="Antonio Ocejo">
<meta name="citation_author_institution" content="Division of Medical Oncology, Jackson Memorial Hospital, Miami, FL USA">
<meta name="citation_author" content="Fatemeh Ardeshir-Larijani">
<meta name="citation_author_institution" content="Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA">
<meta name="citation_author" content="Ticiana Leal">
<meta name="citation_author_institution" content="Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA">
<meta name="citation_author" content="Suresh Ramalingam">
<meta name="citation_author_institution" content="Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA">
<meta name="citation_author" content="Sumaiya Alam">
<meta name="citation_author_institution" content="Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA">
<meta name="citation_author" content="Jhanelle E Gray">
<meta name="citation_author_institution" content="Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL USA">
<meta name="citation_author" content="James Hicks">
<meta name="citation_author_institution" content="Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL USA">
<meta name="citation_author" content="David Kaldas">
<meta name="citation_author_institution" content="Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL USA">
<meta name="citation_author" content="Javier Baena">
<meta name="citation_author_institution" content="Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain">
<meta name="citation_author" content="Maria Zurera Berjaga">
<meta name="citation_author_institution" content="Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain">
<meta name="citation_author" content="Frank Aboubakar Nana">
<meta name="citation_author_institution" content="Division of Pneumology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium">
<meta name="citation_author" content="Christian Grohe">
<meta name="citation_author_institution" content="Klinik für Pneumologie-Evangelische Lungenklinik, Berlin Buch, Berlin, Germany">
<meta name="citation_author" content="Heike Leuders">
<meta name="citation_author_institution" content="Klinik für Pneumologie-Evangelische Lungenklinik, Berlin Buch, Berlin, Germany">
<meta name="citation_author" content="Fabrizio Citarella">
<meta name="citation_author_institution" content="Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy">
<meta name="citation_author" content="Alessio Cortellini">
<meta name="citation_author_institution" content="Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy">
<meta name="citation_author_institution" content="Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy">
<meta name="citation_author_institution" content="Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, UK">
<meta name="citation_author" content="Emanuele Claudio Mingo">
<meta name="citation_author_institution" content="Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy">
<meta name="citation_author" content="Danny Pancirer">
<meta name="citation_author_institution" content="Department of Medicine, Stanford Cancer Institute, Stanford, CA USA">
<meta name="citation_author" content="Millie Das">
<meta name="citation_author_institution" content="Department of Medicine, Stanford Cancer Institute, Stanford, CA USA">
<meta name="citation_author_institution" content="Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA USA">
<meta name="citation_author" content="Timothy John Ellis-Caleo">
<meta name="citation_author_institution" content="Department of Medicine, Stanford Cancer Institute, Stanford, CA USA">
<meta name="citation_author" content="Justin M Cheung">
<meta name="citation_author_institution" content="Department of Medicine, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author" content="Jessica J Lin">
<meta name="citation_author_institution" content="Department of Medicine, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author" content="Alexander S Watson">
<meta name="citation_author_institution" content="Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO USA">
<meta name="citation_author" content="D Ross Camidge">
<meta name="citation_author_institution" content="Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO USA">
<meta name="citation_author" content="Arthi Sridhar">
<meta name="citation_author_institution" content="Division of Medical Oncology, Mayo Clinic, Rochester, MN USA">
<meta name="citation_author" content="Kaushal Parikh">
<meta name="citation_author_institution" content="Division of Medical Oncology, Mayo Clinic, Rochester, MN USA">
<meta name="citation_author" content="Fionnuala Crowley">
<meta name="citation_author_institution" content="Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA">
<meta name="citation_author_institution" content="Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA">
<meta name="citation_author" content="Thomas U Marron">
<meta name="citation_author_institution" content="Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA">
<meta name="citation_author" content="Vanya Aggarwal">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, Georgetown Cancer Institute, Washington, DC USA">
<meta name="citation_author" content="Murtaza Ahmed">
<meta name="citation_author_institution" content="Division of Medical Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA USA">
<meta name="citation_author" content="Kamya Sankar">
<meta name="citation_author_institution" content="Division of Medical Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA USA">
<meta name="citation_author" content="Hassan Kawtharany">
<meta name="citation_author_institution" content="Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS USA">
<meta name="citation_author" content="Jun Zhang">
<meta name="citation_author_institution" content="Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS USA">
<meta name="citation_author" content="Dwight H Owen">
<meta name="citation_author_institution" content="Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH USA">
<meta name="citation_author" content="Mingjia Li">
<meta name="citation_author_institution" content="Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH USA">
<meta name="citation_author" content="Misako Nagasaka">
<meta name="citation_author_institution" content="Department of Medicine, UC Irvine, Irvine, CA USA">
<meta name="citation_author" content="David J Pinato">
<meta name="citation_author_institution" content="Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, UK">
<meta name="citation_author_institution" content="Division of Oncology, Department of Translational Medicine (DIMET), University of Piemonte Orientale, Novara, Italy">
<meta name="citation_author" content="Nichola Awosika">
<meta name="citation_author_institution" content="Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, UK">
<meta name="citation_author" content="Khaled Alhamad">
<meta name="citation_author_institution" content="Division of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT USA">
<meta name="citation_author" content="Sonam Puri">
<meta name="citation_author_institution" content="Division of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT USA">
<meta name="citation_author" content="Unaiza Zaman">
<meta name="citation_author_institution" content="Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA">
<meta name="citation_author" content="Divya M Gupta">
<meta name="citation_author_institution" content="Division of Medical Oncology, Northwestern University, Chicago, IL USA">
<meta name="citation_author" content="Chelsea Lau">
<meta name="citation_author_institution" content="Division of Medical Oncology, Northwestern University, Chicago, IL USA">
<meta name="citation_author" content="Hina Khan">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, Providence, RI USA">
<meta name="citation_author" content="Justin Liauw">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, Providence, RI USA">
<meta name="citation_author" content="Ana I Velazquez">
<meta name="citation_author_institution" content="Division of Medical Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA USA">
<meta name="citation_author" content="Tyiesha Brown">
<meta name="citation_author_institution" content="Division of Medical Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA USA">
<meta name="citation_author" content="Laura Moliner">
<meta name="citation_author_institution" content="Division of Medical Oncology, Institut Catala d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain">
<meta name="citation_author" content="Miguel Mosteiro">
<meta name="citation_author_institution" content="Division of Medical Oncology, Institut Catala d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain">
<meta name="citation_author" content="Pedro Rocha">
<meta name="citation_author_institution" content="Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain">
<meta name="citation_author" content="Mark Evans">
<meta name="citation_author_institution" content="Caris Life Sciences, Phoenix, AZ USA">
<meta name="citation_author" content="Ari Vanderwalde">
<meta name="citation_author_institution" content="Caris Life Sciences, Phoenix, AZ USA">
<meta name="citation_author" content="Andrew Elliott">
<meta name="citation_author_institution" content="Caris Life Sciences, Phoenix, AZ USA">
<meta name="citation_author" content="Jorge Nieva">
<meta name="citation_author_institution" content="Division of Medical Oncology, Norris Cancer Center, University of Southern California, Los Angeles, CA USA">
<meta name="citation_author" content="Gilberto Lopes">
<meta name="citation_author_institution" content="Division of Medical Oncology, Jackson Memorial Hospital, Miami, FL USA">
<meta name="citation_author" content="Patrick C Ma">
<meta name="citation_author_institution" content="Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State University, Hershey, PA USA">
<meta name="citation_author" content="Hossein Borghaei">
<meta name="citation_author_institution" content="Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA USA">
<meta name="citation_author" content="Matthew Lee">
<meta name="citation_author_institution" content="Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY USA">
<meta name="citation_author" content="Lauren Young">
<meta name="citation_author_institution" content="Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY USA">
<meta name="citation_author" content="Raid Aljumaily">
<meta name="citation_author_institution" content="Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA">
<meta name="citation_author" content="Haris Mirza">
<meta name="citation_author_institution" content="Department of Pathology, Yale School of Medicine, New Haven, CT USA">
<meta name="citation_author" content="David J Kwiatkowski">
<meta name="citation_author_institution" content="Division of Pulmonary Medicine, Brigham and Women’s Hospital, Boston, MA USA">
<meta name="citation_author" content="Roy S Herbst">
<meta name="citation_author_institution" content="Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA">
<meta name="citation_author" content="Richard A Flavell">
<meta name="citation_author_institution" content="Department of Immunobiology, Yale University, New Haven, CT USA">
<meta name="citation_author" content="Abdul Rafeh Naqash">
<meta name="citation_author_institution" content="Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA">
<meta name="citation_author" content="Anne C Chiang">
<meta name="citation_author_institution" content="Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="16">
<meta name="citation_firstpage" content="7717">
<meta name="citation_doi" content="10.1038/s41467-025-63091-0">
<meta name="citation_pmid" content="40830141">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365225/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365225/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365225/pdf/41467_2025_Article_63091.pdf">
<meta name="description" content="Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observe comparable overall survival across treatment ...">
<meta name="og:title" content="Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observe comparable overall survival across treatment ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365225/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12365225">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41467-025-63091-0"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41467_2025_Article_63091.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365225%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12365225/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12365225/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365225/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-ncomms.gif" alt="Nature Communications logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Nature Communications" title="Link to Nature Communications" shape="default" href="http://www.nature.com/ncomms/index.html" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Nat Commun</button></div>. 2025 Aug 19;16:7717. doi: <a href="https://doi.org/10.1038/s41467-025-63091-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41467-025-63091-0</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Nat%20Commun%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nat%20Commun%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Nat%20Commun%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Nat%20Commun%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nassar%20AH%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Amin H Nassar</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Amin H Nassar</span></h3>
<div class="p">
<sup>1</sup>Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nassar%20AH%22%5BAuthor%5D" class="usa-link"><span class="name western">Amin H Nassar</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kim%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Chul Kim</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Chul Kim</span></h3>
<div class="p">
<sup>2</sup>Division of Hematology and Oncology, Georgetown Cancer Institute, Washington, DC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kim%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chul Kim</span></a>
</div>
</div>
<sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Adeyelu%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Tolulope Adeyelu</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Tolulope Adeyelu</span></h3>
<div class="p">
<sup>3</sup>Caris Life Sciences, Phoenix, AZ USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Adeyelu%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tolulope Adeyelu</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bou%20Farhat%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Elias Bou Farhat</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Elias Bou Farhat</span></h3>
<div class="p">
<sup>4</sup>Division of Pulmonary Medicine, Brigham and Women’s Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bou%20Farhat%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Elias Bou Farhat</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abushukair%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Hassan Abushukair</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Hassan Abushukair</span></h3>
<div class="p">
<sup>5</sup>Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA </div>
<div class="p">
<sup>6</sup>Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abushukair%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hassan Abushukair</span></a>
</div>
</div>
<sup>5,</sup><sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rakaee%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Mehrdad Rakaee</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Mehrdad Rakaee</span></h3>
<div class="p">
<sup>4</sup>Division of Pulmonary Medicine, Brigham and Women’s Hospital, Boston, MA USA </div>
<div class="p">
<sup>7</sup>Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rakaee%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mehrdad Rakaee</span></a>
</div>
</div>
<sup>4,</sup><sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Matteson%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Kelsey Matteson</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Kelsey Matteson</span></h3>
<div class="p">
<sup>1</sup>Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Matteson%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kelsey Matteson</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lau%20SF%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Shun-Fat Lau</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Shun-Fat Lau</span></h3>
<div class="p">
<sup>8</sup>Department of Immunobiology, Yale University, New Haven, CT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lau%20SF%22%5BAuthor%5D" class="usa-link"><span class="name western">Shun-Fat Lau</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Takabe%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Yamato Takabe</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Yamato Takabe</span></h3>
<div class="p">
<sup>8</sup>Department of Immunobiology, Yale University, New Haven, CT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Takabe%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yamato Takabe</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ocejo%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Antonio Ocejo</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Antonio Ocejo</span></h3>
<div class="p">
<sup>9</sup>Division of Medical Oncology, Jackson Memorial Hospital, Miami, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ocejo%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Antonio Ocejo</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ardeshir-Larijani%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Fatemeh Ardeshir-Larijani</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Fatemeh Ardeshir-Larijani</span></h3>
<div class="p">
<sup>10</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ardeshir-Larijani%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fatemeh Ardeshir-Larijani</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leal%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Ticiana Leal</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Ticiana Leal</span></h3>
<div class="p">
<sup>10</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leal%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Ticiana Leal</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ramalingam%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Suresh Ramalingam</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Suresh Ramalingam</span></h3>
<div class="p">
<sup>10</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ramalingam%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Suresh Ramalingam</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alam%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Sumaiya Alam</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Sumaiya Alam</span></h3>
<div class="p">
<sup>10</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alam%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sumaiya Alam</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gray%20JE%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Jhanelle E Gray</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Jhanelle E Gray</span></h3>
<div class="p">
<sup>11</sup>Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gray%20JE%22%5BAuthor%5D" class="usa-link"><span class="name western">Jhanelle E Gray</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hicks%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">James Hicks</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">James Hicks</span></h3>
<div class="p">
<sup>11</sup>Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hicks%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">James Hicks</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kaldas%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">David Kaldas</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">David Kaldas</span></h3>
<div class="p">
<sup>11</sup>Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kaldas%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">David Kaldas</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Baena%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Javier Baena</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Javier Baena</span></h3>
<div class="p">
<sup>12</sup>Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Baena%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Javier Baena</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Berjaga%20MZ%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Maria Zurera Berjaga</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Maria Zurera Berjaga</span></h3>
<div class="p">
<sup>12</sup>Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Berjaga%20MZ%22%5BAuthor%5D" class="usa-link"><span class="name western">Maria Zurera Berjaga</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nana%20FA%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Frank Aboubakar Nana</span></a><div hidden="hidden" id="id20">
<h3><span class="name western">Frank Aboubakar Nana</span></h3>
<div class="p">
<sup>13</sup>Division of Pneumology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nana%20FA%22%5BAuthor%5D" class="usa-link"><span class="name western">Frank Aboubakar Nana</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Grohe%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Christian Grohe</span></a><div hidden="hidden" id="id21">
<h3><span class="name western">Christian Grohe</span></h3>
<div class="p">
<sup>14</sup>Klinik für Pneumologie-Evangelische Lungenklinik, Berlin Buch, Berlin, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Grohe%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Christian Grohe</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leuders%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Heike Leuders</span></a><div hidden="hidden" id="id22">
<h3><span class="name western">Heike Leuders</span></h3>
<div class="p">
<sup>14</sup>Klinik für Pneumologie-Evangelische Lungenklinik, Berlin Buch, Berlin, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leuders%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Heike Leuders</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Citarella%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Fabrizio Citarella</span></a><div hidden="hidden" id="id23">
<h3><span class="name western">Fabrizio Citarella</span></h3>
<div class="p">
<sup>15</sup>Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Citarella%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fabrizio Citarella</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cortellini%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id24"><span class="name western">Alessio Cortellini</span></a><div hidden="hidden" id="id24">
<h3><span class="name western">Alessio Cortellini</span></h3>
<div class="p">
<sup>15</sup>Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy </div>
<div class="p">
<sup>16</sup>Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy </div>
<div class="p">
<sup>17</sup>Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cortellini%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessio Cortellini</span></a>
</div>
</div>
<sup>15,</sup><sup>16,</sup><sup>17</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mingo%20EC%22%5BAuthor%5D" class="usa-link" aria-describedby="id25"><span class="name western">Emanuele Claudio Mingo</span></a><div hidden="hidden" id="id25">
<h3><span class="name western">Emanuele Claudio Mingo</span></h3>
<div class="p">
<sup>15</sup>Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mingo%20EC%22%5BAuthor%5D" class="usa-link"><span class="name western">Emanuele Claudio Mingo</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pancirer%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id26"><span class="name western">Danny Pancirer</span></a><div hidden="hidden" id="id26">
<h3><span class="name western">Danny Pancirer</span></h3>
<div class="p">
<sup>18</sup>Department of Medicine, Stanford Cancer Institute, Stanford, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pancirer%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Danny Pancirer</span></a>
</div>
</div>
<sup>18</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Das%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id27"><span class="name western">Millie Das</span></a><div hidden="hidden" id="id27">
<h3><span class="name western">Millie Das</span></h3>
<div class="p">
<sup>18</sup>Department of Medicine, Stanford Cancer Institute, Stanford, CA USA </div>
<div class="p">
<sup>19</sup>Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Das%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Millie Das</span></a>
</div>
</div>
<sup>18,</sup><sup>19</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ellis-Caleo%20TJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id28"><span class="name western">Timothy John Ellis-Caleo</span></a><div hidden="hidden" id="id28">
<h3><span class="name western">Timothy John Ellis-Caleo</span></h3>
<div class="p">
<sup>18</sup>Department of Medicine, Stanford Cancer Institute, Stanford, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ellis-Caleo%20TJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Timothy John Ellis-Caleo</span></a>
</div>
</div>
<sup>18</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cheung%20JM%22%5BAuthor%5D" class="usa-link" aria-describedby="id29"><span class="name western">Justin M Cheung</span></a><div hidden="hidden" id="id29">
<h3><span class="name western">Justin M Cheung</span></h3>
<div class="p">
<sup>20</sup>Department of Medicine, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cheung%20JM%22%5BAuthor%5D" class="usa-link"><span class="name western">Justin M Cheung</span></a>
</div>
</div>
<sup>20</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20JJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id30"><span class="name western">Jessica J Lin</span></a><div hidden="hidden" id="id30">
<h3><span class="name western">Jessica J Lin</span></h3>
<div class="p">
<sup>20</sup>Department of Medicine, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20JJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Jessica J Lin</span></a>
</div>
</div>
<sup>20</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Watson%20AS%22%5BAuthor%5D" class="usa-link" aria-describedby="id31"><span class="name western">Alexander S Watson</span></a><div hidden="hidden" id="id31">
<h3><span class="name western">Alexander S Watson</span></h3>
<div class="p">
<sup>21</sup>Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Watson%20AS%22%5BAuthor%5D" class="usa-link"><span class="name western">Alexander S Watson</span></a>
</div>
</div>
<sup>21</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Camidge%20DR%22%5BAuthor%5D" class="usa-link" aria-describedby="id32"><span class="name western">D Ross Camidge</span></a><div hidden="hidden" id="id32">
<h3><span class="name western">D Ross Camidge</span></h3>
<div class="p">
<sup>21</sup>Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Camidge%20DR%22%5BAuthor%5D" class="usa-link"><span class="name western">D Ross Camidge</span></a>
</div>
</div>
<sup>21</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sridhar%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id33"><span class="name western">Arthi Sridhar</span></a><div hidden="hidden" id="id33">
<h3><span class="name western">Arthi Sridhar</span></h3>
<div class="p">
<sup>22</sup>Division of Medical Oncology, Mayo Clinic, Rochester, MN USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sridhar%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Arthi Sridhar</span></a>
</div>
</div>
<sup>22</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Parikh%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id34"><span class="name western">Kaushal Parikh</span></a><div hidden="hidden" id="id34">
<h3><span class="name western">Kaushal Parikh</span></h3>
<div class="p">
<sup>22</sup>Division of Medical Oncology, Mayo Clinic, Rochester, MN USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Parikh%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kaushal Parikh</span></a>
</div>
</div>
<sup>22</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Crowley%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id35"><span class="name western">Fionnuala Crowley</span></a><div hidden="hidden" id="id35">
<h3><span class="name western">Fionnuala Crowley</span></h3>
<div class="p">
<sup>23</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA </div>
<div class="p">
<sup>24</sup>Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Crowley%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fionnuala Crowley</span></a>
</div>
</div>
<sup>23,</sup><sup>24</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Marron%20TU%22%5BAuthor%5D" class="usa-link" aria-describedby="id36"><span class="name western">Thomas U Marron</span></a><div hidden="hidden" id="id36">
<h3><span class="name western">Thomas U Marron</span></h3>
<div class="p">
<sup>23</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Marron%20TU%22%5BAuthor%5D" class="usa-link"><span class="name western">Thomas U Marron</span></a>
</div>
</div>
<sup>23</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aggarwal%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id37"><span class="name western">Vanya Aggarwal</span></a><div hidden="hidden" id="id37">
<h3><span class="name western">Vanya Aggarwal</span></h3>
<div class="p">
<sup>2</sup>Division of Hematology and Oncology, Georgetown Cancer Institute, Washington, DC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aggarwal%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Vanya Aggarwal</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ahmed%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id38"><span class="name western">Murtaza Ahmed</span></a><div hidden="hidden" id="id38">
<h3><span class="name western">Murtaza Ahmed</span></h3>
<div class="p">
<sup>25</sup>Division of Medical Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ahmed%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Murtaza Ahmed</span></a>
</div>
</div>
<sup>25</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sankar%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id39"><span class="name western">Kamya Sankar</span></a><div hidden="hidden" id="id39">
<h3><span class="name western">Kamya Sankar</span></h3>
<div class="p">
<sup>25</sup>Division of Medical Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sankar%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kamya Sankar</span></a>
</div>
</div>
<sup>25</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kawtharany%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id40"><span class="name western">Hassan Kawtharany</span></a><div hidden="hidden" id="id40">
<h3><span class="name western">Hassan Kawtharany</span></h3>
<div class="p">
<sup>26</sup>Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kawtharany%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hassan Kawtharany</span></a>
</div>
</div>
<sup>26</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id41"><span class="name western">Jun Zhang</span></a><div hidden="hidden" id="id41">
<h3><span class="name western">Jun Zhang</span></h3>
<div class="p">
<sup>26</sup>Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jun Zhang</span></a>
</div>
</div>
<sup>26</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Owen%20DH%22%5BAuthor%5D" class="usa-link" aria-describedby="id42"><span class="name western">Dwight H Owen</span></a><div hidden="hidden" id="id42">
<h3><span class="name western">Dwight H Owen</span></h3>
<div class="p">
<sup>27</sup>Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Owen%20DH%22%5BAuthor%5D" class="usa-link"><span class="name western">Dwight H Owen</span></a>
</div>
</div>
<sup>27</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id43"><span class="name western">Mingjia Li</span></a><div hidden="hidden" id="id43">
<h3><span class="name western">Mingjia Li</span></h3>
<div class="p">
<sup>27</sup>Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mingjia Li</span></a>
</div>
</div>
<sup>27</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nagasaka%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id44"><span class="name western">Misako Nagasaka</span></a><div hidden="hidden" id="id44">
<h3><span class="name western">Misako Nagasaka</span></h3>
<div class="p">
<sup>28</sup>Department of Medicine, UC Irvine, Irvine, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nagasaka%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Misako Nagasaka</span></a>
</div>
</div>
<sup>28</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pinato%20DJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id45"><span class="name western">David J Pinato</span></a><div hidden="hidden" id="id45">
<h3><span class="name western">David J Pinato</span></h3>
<div class="p">
<sup>17</sup>Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, UK </div>
<div class="p">
<sup>29</sup>Division of Oncology, Department of Translational Medicine (DIMET), University of Piemonte Orientale, Novara, Italy </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pinato%20DJ%22%5BAuthor%5D" class="usa-link"><span class="name western">David J Pinato</span></a>
</div>
</div>
<sup>17,</sup><sup>29</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Awosika%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id46"><span class="name western">Nichola Awosika</span></a><div hidden="hidden" id="id46">
<h3><span class="name western">Nichola Awosika</span></h3>
<div class="p">
<sup>17</sup>Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Awosika%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nichola Awosika</span></a>
</div>
</div>
<sup>17</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alhamad%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id47"><span class="name western">Khaled Alhamad</span></a><div hidden="hidden" id="id47">
<h3><span class="name western">Khaled Alhamad</span></h3>
<div class="p">
<sup>30</sup>Division of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alhamad%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Khaled Alhamad</span></a>
</div>
</div>
<sup>30</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Puri%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id48"><span class="name western">Sonam Puri</span></a><div hidden="hidden" id="id48">
<h3><span class="name western">Sonam Puri</span></h3>
<div class="p">
<sup>30</sup>Division of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Puri%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sonam Puri</span></a>
</div>
</div>
<sup>30</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zaman%20U%22%5BAuthor%5D" class="usa-link" aria-describedby="id49"><span class="name western">Unaiza Zaman</span></a><div hidden="hidden" id="id49">
<h3><span class="name western">Unaiza Zaman</span></h3>
<div class="p">
<sup>5</sup>Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zaman%20U%22%5BAuthor%5D" class="usa-link"><span class="name western">Unaiza Zaman</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gupta%20DM%22%5BAuthor%5D" class="usa-link" aria-describedby="id50"><span class="name western">Divya M Gupta</span></a><div hidden="hidden" id="id50">
<h3><span class="name western">Divya M Gupta</span></h3>
<div class="p">
<sup>31</sup>Division of Medical Oncology, Northwestern University, Chicago, IL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gupta%20DM%22%5BAuthor%5D" class="usa-link"><span class="name western">Divya M Gupta</span></a>
</div>
</div>
<sup>31</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lau%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id51"><span class="name western">Chelsea Lau</span></a><div hidden="hidden" id="id51">
<h3><span class="name western">Chelsea Lau</span></h3>
<div class="p">
<sup>31</sup>Division of Medical Oncology, Northwestern University, Chicago, IL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lau%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chelsea Lau</span></a>
</div>
</div>
<sup>31</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Khan%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id52"><span class="name western">Hina Khan</span></a><div hidden="hidden" id="id52">
<h3><span class="name western">Hina Khan</span></h3>
<div class="p">
<sup>32</sup>Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, Providence, RI USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Khan%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hina Khan</span></a>
</div>
</div>
<sup>32</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liauw%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id53"><span class="name western">Justin Liauw</span></a><div hidden="hidden" id="id53">
<h3><span class="name western">Justin Liauw</span></h3>
<div class="p">
<sup>32</sup>Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, Providence, RI USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liauw%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Justin Liauw</span></a>
</div>
</div>
<sup>32</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Velazquez%20AI%22%5BAuthor%5D" class="usa-link" aria-describedby="id54"><span class="name western">Ana I Velazquez</span></a><div hidden="hidden" id="id54">
<h3><span class="name western">Ana I Velazquez</span></h3>
<div class="p">
<sup>33</sup>Division of Medical Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Velazquez%20AI%22%5BAuthor%5D" class="usa-link"><span class="name western">Ana I Velazquez</span></a>
</div>
</div>
<sup>33</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Brown%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id55"><span class="name western">Tyiesha Brown</span></a><div hidden="hidden" id="id55">
<h3><span class="name western">Tyiesha Brown</span></h3>
<div class="p">
<sup>33</sup>Division of Medical Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Brown%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tyiesha Brown</span></a>
</div>
</div>
<sup>33</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Moliner%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id56"><span class="name western">Laura Moliner</span></a><div hidden="hidden" id="id56">
<h3><span class="name western">Laura Moliner</span></h3>
<div class="p">
<sup>34</sup>Division of Medical Oncology, Institut Catala d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Moliner%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Laura Moliner</span></a>
</div>
</div>
<sup>34</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mosteiro%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id57"><span class="name western">Miguel Mosteiro</span></a><div hidden="hidden" id="id57">
<h3><span class="name western">Miguel Mosteiro</span></h3>
<div class="p">
<sup>34</sup>Division of Medical Oncology, Institut Catala d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mosteiro%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Miguel Mosteiro</span></a>
</div>
</div>
<sup>34</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rocha%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id58"><span class="name western">Pedro Rocha</span></a><div hidden="hidden" id="id58">
<h3><span class="name western">Pedro Rocha</span></h3>
<div class="p">
<sup>35</sup>Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rocha%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pedro Rocha</span></a>
</div>
</div>
<sup>35</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Evans%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id59"><span class="name western">Mark Evans</span></a><div hidden="hidden" id="id59">
<h3><span class="name western">Mark Evans</span></h3>
<div class="p">
<sup>3</sup>Caris Life Sciences, Phoenix, AZ USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Evans%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mark Evans</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vanderwalde%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id60"><span class="name western">Ari Vanderwalde</span></a><div hidden="hidden" id="id60">
<h3><span class="name western">Ari Vanderwalde</span></h3>
<div class="p">
<sup>3</sup>Caris Life Sciences, Phoenix, AZ USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vanderwalde%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ari Vanderwalde</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elliott%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id61"><span class="name western">Andrew Elliott</span></a><div hidden="hidden" id="id61">
<h3><span class="name western">Andrew Elliott</span></h3>
<div class="p">
<sup>3</sup>Caris Life Sciences, Phoenix, AZ USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elliott%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Andrew Elliott</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nieva%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id62"><span class="name western">Jorge Nieva</span></a><div hidden="hidden" id="id62">
<h3><span class="name western">Jorge Nieva</span></h3>
<div class="p">
<sup>36</sup>Division of Medical Oncology, Norris Cancer Center, University of Southern California, Los Angeles, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nieva%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jorge Nieva</span></a>
</div>
</div>
<sup>36</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lopes%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id63"><span class="name western">Gilberto Lopes</span></a><div hidden="hidden" id="id63">
<h3><span class="name western">Gilberto Lopes</span></h3>
<div class="p">
<sup>9</sup>Division of Medical Oncology, Jackson Memorial Hospital, Miami, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lopes%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gilberto Lopes</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20PC%22%5BAuthor%5D" class="usa-link" aria-describedby="id64"><span class="name western">Patrick C Ma</span></a><div hidden="hidden" id="id64">
<h3><span class="name western">Patrick C Ma</span></h3>
<div class="p">
<sup>37</sup>Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State University, Hershey, PA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20PC%22%5BAuthor%5D" class="usa-link"><span class="name western">Patrick C Ma</span></a>
</div>
</div>
<sup>37</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Borghaei%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id65"><span class="name western">Hossein Borghaei</span></a><div hidden="hidden" id="id65">
<h3><span class="name western">Hossein Borghaei</span></h3>
<div class="p">
<sup>38</sup>Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Borghaei%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hossein Borghaei</span></a>
</div>
</div>
<sup>38</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lee%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id66"><span class="name western">Matthew Lee</span></a><div hidden="hidden" id="id66">
<h3><span class="name western">Matthew Lee</span></h3>
<div class="p">
<sup>39</sup>Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lee%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Matthew Lee</span></a>
</div>
</div>
<sup>39</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Young%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id67"><span class="name western">Lauren Young</span></a><div hidden="hidden" id="id67">
<h3><span class="name western">Lauren Young</span></h3>
<div class="p">
<sup>39</sup>Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Young%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lauren Young</span></a>
</div>
</div>
<sup>39</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aljumaily%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id68"><span class="name western">Raid Aljumaily</span></a><div hidden="hidden" id="id68">
<h3><span class="name western">Raid Aljumaily</span></h3>
<div class="p">
<sup>5</sup>Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aljumaily%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Raid Aljumaily</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mirza%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id69"><span class="name western">Haris Mirza</span></a><div hidden="hidden" id="id69">
<h3><span class="name western">Haris Mirza</span></h3>
<div class="p">
<sup>40</sup>Department of Pathology, Yale School of Medicine, New Haven, CT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mirza%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Haris Mirza</span></a>
</div>
</div>
<sup>40</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kwiatkowski%20DJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id70"><span class="name western">David J Kwiatkowski</span></a><div hidden="hidden" id="id70">
<h3><span class="name western">David J Kwiatkowski</span></h3>
<div class="p">
<sup>4</sup>Division of Pulmonary Medicine, Brigham and Women’s Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kwiatkowski%20DJ%22%5BAuthor%5D" class="usa-link"><span class="name western">David J Kwiatkowski</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Herbst%20RS%22%5BAuthor%5D" class="usa-link" aria-describedby="id71"><span class="name western">Roy S Herbst</span></a><div hidden="hidden" id="id71">
<h3><span class="name western">Roy S Herbst</span></h3>
<div class="p">
<sup>1</sup>Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Herbst%20RS%22%5BAuthor%5D" class="usa-link"><span class="name western">Roy S Herbst</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Flavell%20RA%22%5BAuthor%5D" class="usa-link" aria-describedby="id72"><span class="name western">Richard A Flavell</span></a><div hidden="hidden" id="id72">
<h3><span class="name western">Richard A Flavell</span></h3>
<div class="p">
<sup>8</sup>Department of Immunobiology, Yale University, New Haven, CT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Flavell%20RA%22%5BAuthor%5D" class="usa-link"><span class="name western">Richard A Flavell</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Naqash%20AR%22%5BAuthor%5D" class="usa-link" aria-describedby="id73"><span class="name western">Abdul Rafeh Naqash</span></a><div hidden="hidden" id="id73">
<h3><span class="name western">Abdul Rafeh Naqash</span></h3>
<div class="p">
<sup>5</sup>Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Naqash%20AR%22%5BAuthor%5D" class="usa-link"><span class="name western">Abdul Rafeh Naqash</span></a>
</div>
</div>
<sup>5,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chiang%20AC%22%5BAuthor%5D" class="usa-link" aria-describedby="id74"><span class="name western">Anne C Chiang</span></a><div hidden="hidden" id="id74">
<h3><span class="name western">Anne C Chiang</span></h3>
<div class="p">
<sup>1</sup>Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chiang%20AC%22%5BAuthor%5D" class="usa-link"><span class="name western">Anne C Chiang</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT USA </div>
<div id="Aff2">
<sup>2</sup>Division of Hematology and Oncology, Georgetown Cancer Institute, Washington, DC USA </div>
<div id="Aff3">
<sup>3</sup>Caris Life Sciences, Phoenix, AZ USA </div>
<div id="Aff4">
<sup>4</sup>Division of Pulmonary Medicine, Brigham and Women’s Hospital, Boston, MA USA </div>
<div id="Aff5">
<sup>5</sup>Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA </div>
<div id="Aff6">
<sup>6</sup>Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA </div>
<div id="Aff7">
<sup>7</sup>Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway </div>
<div id="Aff8">
<sup>8</sup>Department of Immunobiology, Yale University, New Haven, CT USA </div>
<div id="Aff9">
<sup>9</sup>Division of Medical Oncology, Jackson Memorial Hospital, Miami, FL USA </div>
<div id="Aff10">
<sup>10</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA USA </div>
<div id="Aff11">
<sup>11</sup>Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL USA </div>
<div id="Aff12">
<sup>12</sup>Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain </div>
<div id="Aff13">
<sup>13</sup>Division of Pneumology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium </div>
<div id="Aff14">
<sup>14</sup>Klinik für Pneumologie-Evangelische Lungenklinik, Berlin Buch, Berlin, Germany </div>
<div id="Aff15">
<sup>15</sup>Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy </div>
<div id="Aff16">
<sup>16</sup>Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy </div>
<div id="Aff17">
<sup>17</sup>Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, UK </div>
<div id="Aff18">
<sup>18</sup>Department of Medicine, Stanford Cancer Institute, Stanford, CA USA </div>
<div id="Aff19">
<sup>19</sup>Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA USA </div>
<div id="Aff20">
<sup>20</sup>Department of Medicine, Massachusetts General Hospital, Boston, MA USA </div>
<div id="Aff21">
<sup>21</sup>Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO USA </div>
<div id="Aff22">
<sup>22</sup>Division of Medical Oncology, Mayo Clinic, Rochester, MN USA </div>
<div id="Aff23">
<sup>23</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA </div>
<div id="Aff24">
<sup>24</sup>Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA </div>
<div id="Aff25">
<sup>25</sup>Division of Medical Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA USA </div>
<div id="Aff26">
<sup>26</sup>Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS USA </div>
<div id="Aff27">
<sup>27</sup>Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH USA </div>
<div id="Aff28">
<sup>28</sup>Department of Medicine, UC Irvine, Irvine, CA USA </div>
<div id="Aff29">
<sup>29</sup>Division of Oncology, Department of Translational Medicine (DIMET), University of Piemonte Orientale, Novara, Italy </div>
<div id="Aff30">
<sup>30</sup>Division of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT USA </div>
<div id="Aff31">
<sup>31</sup>Division of Medical Oncology, Northwestern University, Chicago, IL USA </div>
<div id="Aff32">
<sup>32</sup>Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, Providence, RI USA </div>
<div id="Aff33">
<sup>33</sup>Division of Medical Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA USA </div>
<div id="Aff34">
<sup>34</sup>Division of Medical Oncology, Institut Catala d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain </div>
<div id="Aff35">
<sup>35</sup>Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain </div>
<div id="Aff36">
<sup>36</sup>Division of Medical Oncology, Norris Cancer Center, University of Southern California, Los Angeles, CA USA </div>
<div id="Aff37">
<sup>37</sup>Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State University, Hershey, PA USA </div>
<div id="Aff38">
<sup>38</sup>Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA USA </div>
<div id="Aff39">
<sup>39</sup>Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY USA </div>
<div id="Aff40">
<sup>40</sup>Department of Pathology, Yale School of Medicine, New Haven, CT USA </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 11; Accepted 2025 Aug 4; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12365225  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830141/" class="usa-link">40830141</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observe comparable overall survival across treatment regimens (chemotherapy, chemoimmunotherapy, immunotherapy) without unexpected adverse events. Genomic analysis identifies distinct non-small cell lung cancer-like (NSCLC-like, <em>KEAP1</em>, <em>KRAS</em>, <em>STK11</em> mutations) and SCLC-like (<em>RB1</em>, <em>TP53</em> mutations) LCNEC subtypes, with 80% aligning with SCLC transcriptional profiles. Serial sampling reveals stable mutational but shifting transcriptomic landscapes over time. Here we show, elevated FGL-1 (a LAG-3 ligand) and SPINK1 expression in NSCLC-like LCNECs, and higher levels of DLL3 in SCLC-like LCNECs. Immunofluorescence confirms FGL-1 expression in NSCLC-like LCNECs, and H&amp;E slide analyses indicates fewer tumor-infiltrating lymphocytes in LCNECs versus other lung cancers. These findings highlight LCNEC’s distinct immunogenomic profile, supporting future investigations into LAG-3, SPINK1, and DLL3-targeted therapies.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Subject terms:</strong> Lung cancer, Immunotherapy, Lung cancer, Tumour biomarkers</p></section></section><section class="abstract" id="Abs2"><hr class="headless">
<p id="Par2">Pulmonary large cell neuroendocrine carcinoma is an aggressive subtype of lung cancer. Here, the authors identify distinct subtypes based on genomic alterations and transcriptomic alterations.</p></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par3">Under the 2015 World Health Organization (WHO) guidelines, pulmonary large cell neuroendocrine carcinoma (LCNEC) is classified as a high-grade neuroendocrine tumor<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a></sup>. For patients with advanced LCNEC, median survival is typically between 7 and 12 months<sup><a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup>. However, optimal systemic treatment strategies for this aggressive disease remain undefined due to limited data. Compounding the challenge is the scarcity of clinical studies and the relative rarity of LCNEC, which accounts for only 3% of all lung carcinomas<sup><a href="#CR3" class="usa-link" aria-describedby="CR3">3</a></sup>. At the core of this issue lies the unresolved biological relationship between LCNEC and other lung neoplasms. Gene expression and limited genomic studies have produced inconsistent findings on the connection between LCNEC and small cell lung cancer (SCLC), with certain reports indicating highly similar biology<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup> while others have suggested distinct gene expression and mutational profiles<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>,<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a></sup>. Additionally, molecular alterations typical of adenocarcinoma, such as <em>EGFR</em> mutations<sup><a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>,<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a></sup>, <em>ALK</em> rearrangements<sup><a href="#CR9" class="usa-link" aria-describedby="CR9">9</a></sup>, and <em>KRAS</em> mutations<sup><a href="#CR10" class="usa-link" aria-describedby="CR10">10</a></sup>, have been identified in LCNEC without adenocarcinoma components, sharply contrasting with classic de novo SC.</p>
<p id="Par4">Previous integrative genomic and transcriptomic analyses of 75 LCNECs delineated two distinct molecular subtypes—Type I, characterized by co-occurring <em>TP53</em> and <em>STK11/KEAP1</em> alterations, and Type II, defined by bi-allelic inactivation of <em>TP53</em> and <em>RB1</em><sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup>. Despite overlapping genomic landscapes, these subtypes demonstrated divergent transcriptional programs: Type I LCNECs display a neuroendocrine-enriched phenotype marked by ASCL1 and DLL3 expression with attenuated NOTCH signaling, whereas Type II LCNECs demonstrate diminished neuroendocrine differentiation, heightened NOTCH pathway activity, and enrichment of immune-related signatures. This discordance between mutational architecture and transcriptional identity underscores the biological heterogeneity of LCNEC and challenges reductionist models that rely solely on genomic alterations for subtype classification.</p>
<p id="Par5">Recent genomic analyses have indicated that LCNEC can be divided into non-small cell lung cancer (NSCLC)-like (characterized by lack of <em>RB1</em> genomic alterations and presence of mutations in the <em>KRAS</em>, <em>STK11</em>, and <em>KEAP1</em> genes) and SCLC-like genomic subtypes (characterized by concurrent <em>TP53</em> and <em>RB1</em> mutations or loss)<sup><a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>,<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>–<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup>. Unfortunately, patients with advanced LCNEC consistently exhibit poor outcomes regardless of the molecular subtype, underscoring the urgent need for new treatment paradigms<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup>.</p>
<p id="Par6">Immune checkpoint inhibitors (ICIs) have markedly revolutionized the treatment landscape for various cancers, including both NSCLC and SCLC<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>–<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a></sup>. However, the clinical efficacy data of ICIs in advanced LCNEC predominantly stems from case reports and small retrospective studies<sup><a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>,<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>–<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup>. A recent analysis of 125 patients with advanced LCNEC suggested a potential survival benefit from immunotherapy-based regimens<sup><a href="#CR32" class="usa-link" aria-describedby="CR32">32</a></sup>. However, all patients received ICIs after front-line therapy—a treatment sequence no longer standard in NSCLC and SCLC. Prospective evaluation of ICIs in LCNEC is in its infancy, with only a small number of patients enrolled across several ongoing clinical trials (<a href="https://clinicaltrials.gov/ct2/show/NCT03352934" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03352934</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT03190213" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03190213</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT03136055" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03136055</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT03290079" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03290079</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT03728361" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03728361</a><sup><a href="#CR33" class="usa-link" aria-describedby="CR33">33</a></sup>, NCT0283401), and biomarker data remain sparse. Given the paucity of effective systemic therapies for LCNEC, there is an urgent need for strategies to improve outcomes. In this study, we analyze two independent cohorts comprising 590 patients with advanced LCNEC to define survival outcomes by front-line treatment regimen, including those incorporating ICIs. Through integrative analyses—spanning targeted and whole-exome sequencing (WES), digital pathology with machine learning, and whole-transcriptome sequencing (WTS)—we identify therapeutic targets and molecular vulnerabilities, informing future clinical trial development.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Characteristics of clinical cohorts</h3>
<p id="Par7">Cohort 1 consisted of 217 patients with LCNEC treated with first-line systemic treatments. Cohort 2 comprised 373 patients diagnosed with LCNEC, of whom a subset had available data on first-line systemic treatment (<em>n</em> = 146; Table <a href="#Tab1" class="usa-link">1</a>, Supplementary Fig. <a href="#MOESM1" class="usa-link">1</a>, Supplementary Data <a href="#MOESM5" class="usa-link">2</a> and <a href="#MOESM5" class="usa-link">3</a>). Median age was 66 years (range: 18–88) and 67 (range: 38–89) for Cohorts 1 and 2, respectively (Table <a href="#Tab1" class="usa-link">1</a>, Supplementary Data <a href="#MOESM5" class="usa-link">2</a> and <a href="#MOESM5" class="usa-link">3</a>). The median follow-up time for Cohorts 1 and 2 was 48.6 months (95% CI: 38–62) and 29.5 months (95% CI: 25.3–36.7), respectively. The majority of patients identified as white in both cohorts (Cohort 1: <em>n</em> = 168, 81%, Cohort 2: <em>n</em> = 238, 64%; Table <a href="#Tab1" class="usa-link">1</a>). For patients with available systemic treatment data, treatment regimens included chemotherapy (<em>n</em> = 121 (56%) for Cohort 1, <em>n</em> = 46 (32%) for Cohort 2), chemoimmunotherapy (<em>n</em> = 82 (38%) for Cohort 1, <em>n</em> = 88 (60%) for Cohort 2), and immunotherapy (<em>n</em> = 14 (6.4%) for Cohort 1, <em>n</em> = 12 (8.2%) for Cohort 2). There were no differences in baseline characteristics across the 3 systemic treatments (Table <a href="#Tab1" class="usa-link">1</a>).</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Baseline clinico-pathologic characteristics of patients with pure LCNEC in Cohorts 1 and 2</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="5" rowspan="1">Cohort 1</th>
<th colspan="4" rowspan="1">Cohort 2</th>
</tr>
<tr>
<th colspan="1" rowspan="1">Clinical characteristic</th>
<th colspan="1" rowspan="1">LCNEC Total (<em>N</em> = 217)</th>
<th colspan="1" rowspan="1">SCLC-like LCNEC (<em>N</em> = 19)</th>
<th colspan="1" rowspan="1">NSCLC-like LCNEC (<em>N</em> = 25)</th>
<th colspan="1" rowspan="1">Unclassified (<em>N</em> = 41)</th>
<th colspan="1" rowspan="1">Unknown (<em>N</em> = 132)</th>
<th colspan="1" rowspan="1">LCNEC Total (<em>N</em> = 373)</th>
<th colspan="1" rowspan="1">SCLC-like LCNEC (<em>N</em> = 136)</th>
<th colspan="1" rowspan="1">NSCLC-like LCNEC (<em>N</em> = 89)</th>
<th colspan="1" rowspan="1">Unclassified (<em>N</em> = 148)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>Age</strong><sup>a</sup>
<strong>(Median, IQR)</strong>
</td>
<td align="left" colspan="1" rowspan="1">66 (59–71)</td>
<td align="left" colspan="1" rowspan="1">69 (53–70)</td>
<td align="left" colspan="1" rowspan="1">63 (57–72)</td>
<td align="left" colspan="1" rowspan="1">63 (52–70)</td>
<td align="left" colspan="1" rowspan="1">67 (61–72)</td>
<td align="left" colspan="1" rowspan="1">67 (38–89)</td>
<td align="left" colspan="1" rowspan="1">68 (38–89)</td>
<td align="left" colspan="1" rowspan="1">63 (45–83)</td>
<td align="left" colspan="1" rowspan="1">69 (40–88)</td>
</tr>
<tr><td colspan="10" rowspan="1"><strong>Sex</strong></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Females</td>
<td align="left" colspan="1" rowspan="1">97 (45%)</td>
<td align="left" colspan="1" rowspan="1">10 (53%)</td>
<td align="left" colspan="1" rowspan="1">15 (60%)</td>
<td align="left" colspan="1" rowspan="1">16 (39%)</td>
<td align="left" colspan="1" rowspan="1">56 (42%)</td>
<td align="left" colspan="1" rowspan="1">175 (47%)</td>
<td align="left" colspan="1" rowspan="1">72 (53%)</td>
<td align="left" colspan="1" rowspan="1">45 (51%)</td>
<td align="left" colspan="1" rowspan="1">67 (45%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Males</td>
<td align="left" colspan="1" rowspan="1">120 (55%)</td>
<td align="left" colspan="1" rowspan="1">9 (47%)</td>
<td align="left" colspan="1" rowspan="1">10 (40%)</td>
<td align="left" colspan="1" rowspan="1">25 (61%)</td>
<td align="left" colspan="1" rowspan="1">76 (58%)</td>
<td align="left" colspan="1" rowspan="1">198 (53%)</td>
<td align="left" colspan="1" rowspan="1">64 (47%)</td>
<td align="left" colspan="1" rowspan="1">44 (49%)</td>
<td align="left" colspan="1" rowspan="1">81 (55%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not reported<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
</tr>
<tr><td colspan="10" rowspan="1"><strong>Race</strong></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Asian</td>
<td align="left" colspan="1" rowspan="1">7 (3.4%)</td>
<td align="left" colspan="1" rowspan="1">1 (5.6%)</td>
<td align="left" colspan="1" rowspan="1">2 (8.3%)</td>
<td align="left" colspan="1" rowspan="1">2 (5.1%)</td>
<td align="left" colspan="1" rowspan="1">2 (1.6%)</td>
<td align="left" colspan="1" rowspan="1">7 (2.3%)</td>
<td align="left" colspan="1" rowspan="1">2 (1.8%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td align="left" colspan="1" rowspan="1">5 (4%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Black</td>
<td align="left" colspan="1" rowspan="1">28 (13.5%)</td>
<td align="left" colspan="1" rowspan="1">1 (5.6%)</td>
<td align="left" colspan="1" rowspan="1">2 (8.3%)</td>
<td align="left" colspan="1" rowspan="1">4 (10%)</td>
<td align="left" colspan="1" rowspan="1">21 (17%)</td>
<td align="left" colspan="1" rowspan="1">48 (16%)</td>
<td align="left" colspan="1" rowspan="1">15 (13%)</td>
<td align="left" colspan="1" rowspan="1">9 (13%)</td>
<td align="left" colspan="1" rowspan="1">24 (19%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">White</td>
<td align="left" colspan="1" rowspan="1">168 (81%)</td>
<td align="left" colspan="1" rowspan="1">15 (83%)</td>
<td align="left" colspan="1" rowspan="1">18 (75)</td>
<td align="left" colspan="1" rowspan="1">33 (85%)</td>
<td align="left" colspan="1" rowspan="1">102 (80%)</td>
<td align="left" colspan="1" rowspan="1">238 (77%)</td>
<td align="left" colspan="1" rowspan="1">92 (82%)</td>
<td align="left" colspan="1" rowspan="1">57 (81%)</td>
<td align="left" colspan="1" rowspan="1">89 (71%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other</td>
<td align="left" colspan="1" rowspan="1">5 (2.4%)</td>
<td align="left" colspan="1" rowspan="1">1 (5.6%)</td>
<td align="left" colspan="1" rowspan="1">2 (8.3%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td align="left" colspan="1" rowspan="1">2 (1.6%)</td>
<td align="left" colspan="1" rowspan="1">15 (4.9%)</td>
<td align="left" colspan="1" rowspan="1">3 (2.7%)</td>
<td align="left" colspan="1" rowspan="1">4 (5.7%)</td>
<td align="left" colspan="1" rowspan="1">8 (6.3%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not reported<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">9</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">65</td>
<td align="left" colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">19</td>
<td align="left" colspan="1" rowspan="1">22</td>
</tr>
<tr><td colspan="10" rowspan="1"><strong>PD-L1 TPS</strong></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt;1%</td>
<td align="left" colspan="1" rowspan="1">91 (68%)</td>
<td align="left" colspan="1" rowspan="1">9 (64%)</td>
<td align="left" colspan="1" rowspan="1">11 (85%)</td>
<td align="left" colspan="1" rowspan="1">22 (69%)</td>
<td align="left" colspan="1" rowspan="1">49 (65%)</td>
<td align="left" colspan="1" rowspan="1">269 (75%)</td>
<td align="left" colspan="1" rowspan="1">98 (75%)</td>
<td align="left" colspan="1" rowspan="1">64 (77%)</td>
<td align="left" colspan="1" rowspan="1">107 (75%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">1–49%</td>
<td align="left" colspan="1" rowspan="1">37 (28%)</td>
<td align="left" colspan="1" rowspan="1">4 (29%)</td>
<td align="left" colspan="1" rowspan="1">2 (15%)</td>
<td align="left" colspan="1" rowspan="1">7 (22%)</td>
<td align="left" colspan="1" rowspan="1">24 (32%)</td>
<td align="left" colspan="1" rowspan="1">67 (19%)</td>
<td align="left" colspan="1" rowspan="1">27 (21%)</td>
<td align="left" colspan="1" rowspan="1">14 (17%)</td>
<td align="left" colspan="1" rowspan="1">26 (18%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥50%</td>
<td align="left" colspan="1" rowspan="1">6 (4%)</td>
<td align="left" colspan="1" rowspan="1">1 (7%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td align="left" colspan="1" rowspan="1">3 (9%)</td>
<td align="left" colspan="1" rowspan="1">2 (3%)</td>
<td align="left" colspan="1" rowspan="1">20 (5.5%)</td>
<td align="left" colspan="1" rowspan="1">6 (4.6%)</td>
<td align="left" colspan="1" rowspan="1">5 (6%)</td>
<td align="left" colspan="1" rowspan="1">9 (6.3%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not reported<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">83</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">9</td>
<td align="left" colspan="1" rowspan="1">57</td>
<td align="left" colspan="1" rowspan="1">13</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr><td colspan="10" rowspan="1"><strong>1st line systemic treatment category</strong></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chemotherapy</td>
<td align="left" colspan="1" rowspan="1">121 (56%)</td>
<td align="left" colspan="1" rowspan="1">8 (42%)</td>
<td align="left" colspan="1" rowspan="1">12 (48%)</td>
<td align="left" colspan="1" rowspan="1">23 (56%)</td>
<td align="left" colspan="1" rowspan="1">78 (59%)</td>
<td align="left" colspan="1" rowspan="1">46 (32%)</td>
<td align="left" colspan="1" rowspan="1">18 (31%)</td>
<td align="left" colspan="1" rowspan="1">13 (33%)</td>
<td align="left" colspan="1" rowspan="1">15 (31%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chemoimmunotherapy</td>
<td align="left" colspan="1" rowspan="1">82 (38%)</td>
<td align="left" colspan="1" rowspan="1">11 (58%)</td>
<td align="left" colspan="1" rowspan="1">11 (44%)</td>
<td align="left" colspan="1" rowspan="1">13 (32%)</td>
<td align="left" colspan="1" rowspan="1">47 (36%)</td>
<td align="left" colspan="1" rowspan="1">88 (60%)</td>
<td align="left" colspan="1" rowspan="1">35 (60.3%)</td>
<td align="left" colspan="1" rowspan="1">22 (56%)</td>
<td align="left" colspan="1" rowspan="1">31 (63%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Immunotherapy</td>
<td align="left" colspan="1" rowspan="1">14 (6%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td align="left" colspan="1" rowspan="1">2 (8%)</td>
<td align="left" colspan="1" rowspan="1">5 (12%)</td>
<td align="left" colspan="1" rowspan="1">7 (5%)</td>
<td align="left" colspan="1" rowspan="1">12 (8.3%)</td>
<td align="left" colspan="1" rowspan="1">5 (8.6%)</td>
<td align="left" colspan="1" rowspan="1">4 (10%)</td>
<td align="left" colspan="1" rowspan="1">3 (6.1%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not reported<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">227</td>
<td align="left" colspan="1" rowspan="1">78</td>
<td align="left" colspan="1" rowspan="1">50</td>
<td align="left" colspan="1" rowspan="1">99</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p9">
<p><sup>a</sup>At initiation of systemic therapy for Cohort 1; at time of diagnosis for Cohort 2.</p>
<p><sup>b</sup>Not included in denominator.</p>
</div></div></section></section><section id="Sec4"><h3 class="pmc_sec_title">Survival outcomes to first-line systemic therapy</h3>
<p id="Par8">There was no significant difference in median OS across the 3 treatment groups in both cohorts (Fig. <a href="#Fig1" class="usa-link">1A, B</a>). In Cohort 1, median OS was 15 months (95% CI: 8.1–17.4) in the chemotherapy group, 12 months (95% CI: 7.4–18.3) in the chemoimmunotherapy group, and 13.6 months (95% CI: 6.8–25.2) in the immunotherapy group. In Cohort 2, median OS was 14.9 months (95% CI: 9.3–26.1) in the chemotherapy group, 17.6 months (95% CI: 13.2–21.2) in the chemoimmunotherapy group, and 21.7 months (95% CI: 6.0–NR) in the immunotherapy group. To evaluate the potential influence of treatment year on clinical outcomes, we first performed an analysis of OS within the chemotherapy-treated cohort. The analysis revealed no significant difference in OS between patients treated prior to January 1, 2019 (<em>n</em> = 71), and those treated thereafter (<em>n</em> = 48; <em>p</em> = 0.57). Subsequently, we compared OS among patients treated with chemotherapy alone (<em>n</em> = 32) versus immunotherapy alone (<em>n</em> = 8) versus those treated with chemoimmunotherapy (<em>n</em> = 74) after March 1st, 2019, and similarly observed no significant difference (<em>p</em> = 0.3). Among patients who received chemotherapy as first-line systemic treatment, 61 went on to receive a subsequent line of therapy (28 non-ICI-based, 33 ICI-based). Within this group, there was no significant difference between patients who received subsequent ICI-based therapy and those who received non-ICI-based therapy (<em>p</em> = 0.2). In Cohort 2, there was no significant difference in OS between patients with NSCLC-like LCNECs who received NSCLC-based chemotherapy regimens and those with SCLC-like LCNECs treated with SCLC-based chemotherapy regimens (HR = 1.20, 95% CI: 0.59–2.31, <em>p</em> = 0.65, Supplementary Fig. <a href="#MOESM1" class="usa-link">2</a>). In Cohort 1, this analysis was limited by small sample size (<em>n</em> = 5 per group), and thus underpowered to detect meaningful differences.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1. Clinical outcomes of first-line treatment options in Cohorts 1 and 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365225_41467_2025_63091_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec1a/12365225/c39108be760d/41467_2025_63091_Fig1_HTML.jpg" loading="lazy" id="d33e1791" height="444" width="800" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan–Meier analysis of <strong>A</strong> overall survival (OS) in Cohort 1, <strong>B</strong> OS in Cohort 2, and <strong>C</strong> real-world progression-free survival (rwPFS) in Cohort 1, comparing patients with pulmonary large cell neuroendocrine carcinoma treated with chemotherapy (<em>n</em> = 119 for Cohort 1, <em>n</em> = 47 for Cohort 2), chemoimmunotherapy (<em>n</em> = 81 for Cohort 1, <em>n</em> = 99 for Cohort 2), or immunotherapy (<em>n</em> = 14 for Cohort 1, <em>n</em> = 12 for Cohort 2). Survival distributions were compared using a two-sided log-rank test. <strong>D</strong> Tornado plot depicting treatment-related adverse events for patients treated with any first-line systemic therapy in Cohort 1 (<em>n</em> = 216). Any grade (right) and ≥grade 3 (left). HR hazard ratio, ref reference. Statistical significance is defined as <em>p</em> &lt; 0.05.</p></figcaption></figure><p id="Par9">In the ICI-treated group from Cohort 2, six patients exhibited a real-world overall survival (rwOS) exceeding 20 months. Among these, 33% (2 out of 6) demonstrated high TMB, and 50% (3 out of 6) were positive for programmed death-ligand 1 (PD-L1) expression. In patients receiving ICI-based therapies, GSEA revealed a significant enrichment of pro-inflammatory immune pathways in those with a rwOS exceeding 20 months compared to those with an rwOS of less than 20 months (Supplementary Fig. <a href="#MOESM1" class="usa-link">3</a>). Expanding the biomarker analysis to include the chemoimmunotherapy group in Cohort 2, where the sample size permitted more robust comparisons, the median rwOS was not significantly different between TMB-high (&gt;19) versus TMB-low tumors (≤19; <em>p</em> = 0.7, Supplementary Fig. <a href="#MOESM1" class="usa-link">4A</a>). Furthermore, within the chemoimmunotherapy group, rwOS did not significantly differ based on PD-L1 status (<em>p</em> = 0.5, Supplementary Fig. <a href="#MOESM1" class="usa-link">4B</a>).</p>
<p id="Par10">Among the 216 evaluable patients in Cohort 1, median rwPFS was 5.1 months (95% CI: 3.4–5.5) in the chemotherapy group, 5.4 months (95% CI: 4.4–6.1) in the chemoimmunotherapy group, and 3.9 months in the immunotherapy group (95% CI: 2–6.5). After adjusting for ECOG, M stage, sex, and age, the chemotherapy group had a statistically significantly lower rwPFS compared to the chemoimmunotherapy group (<em>p</em> = 0.03; HR: 1.43 [95% CI: 1.04–1.99]). In contrast, the immunotherapy group did not show a significant difference in rwPFS (HR: 1.3 [95% CI: 0.69–2.58]) (Fig. <a href="#Fig1" class="usa-link">1C</a>). In Cohort 2, rwPFS was not available, so ToT was used as a surrogate endpoint. Median ToT was 2.4 months (95% CI: 2.1–3.6) in the chemotherapy group, 7.5 months (95% CI: 5.2–10.4) in the chemoimmunotherapy group, and 6.3 months (95% CI: 1.3–18.0) in the immunotherapy group. Patients treated with chemotherapy had significantly worse ToT compared to those receiving chemoimmunotherapy (HR: 1.44, <em>p</em> = 0.05, Supplementary Fig. <a href="#MOESM1" class="usa-link">5</a>).</p></section><section id="Sec5"><h3 class="pmc_sec_title">Toxicity profiles in Cohort 1</h3>
<p id="Par11">Overall, 112 (52%) patients developed treatment-related adverse events (trAE) of any grade (Fig. <a href="#Fig1" class="usa-link">1D</a>) with similar frequencies across treatment groups (chemotherapy: <em>n</em> = 61, 50%; chemoimmunotherapy: <em>n</em> = 45, 55%; immunotherapy: <em>n</em> = 6, 43%). Grade ≥ 3 trAE occurred in 22% (95% CI: 16–31), 26% (95% CI: 17–36), and 0% (95% CI: 0–22) patients in the chemotherapy, chemoimmunotherapy, and immunotherapy groups, respectively (Supplementary Fig. <a href="#MOESM1" class="usa-link">6</a>). Toxicity led to discontinuation of systemic treatment in 10% (95% CI: 5.8–17), 15% (95% CI: 8.6– 24), and 14% (95% CI: 2.5–40) patients in the chemotherapy, chemoimmunotherapy, and immunotherapy groups, respectively (Supplementary Data <a href="#MOESM5" class="usa-link">4</a>).</p></section><section id="Sec6"><h3 class="pmc_sec_title">Genomic map and clinical outcomes of LCNEC molecular subtypes</h3>
<p id="Par12">Prior genomic mapping of LCNEC has delineated these tumors into SCLC-like and NSCLC-like categories<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup>. Utilizing a similar stratification approach, we classified 217 tumors in Cohort 1 into SCLC-like (characterized by concurrent <em>TP53</em> and <em>RB1</em> mutations) and NSCLC-like (characterized by mutations in either <em>STK11</em>, <em>KRAS</em>, or <em>KEAP1</em> and wild-type <em>RB1</em> status). Tumors that did not conform to either of these subtypes were designated as unclassified. In Cohort 1, 85 patients had genomic data that allowed molecular classification. Of these, 25 (29%) were classified as NSCLC-like, 19 (22%) were SCLC-like, and 41 (48%) were unclassified (Fig. <a href="#Fig2" class="usa-link">2A</a>, Supplementary Fig. <a href="#MOESM1" class="usa-link">1</a>, Supplementary Data <a href="#MOESM5" class="usa-link">5</a>). The remainder of tumors (<em>n</em> = 132) did not have full mutation profiling of the genes of interest (<em>KEAP1</em>, <em>KRAS</em>, <em>STK11</em>, <em>TP53</em>, and <em>RB1</em>) and thus were labeled unknown. In Cohort 2, 89 (23.9%) tumors were genomically NSCLC-like, 136 (36.5%)were SCLC-like, and 148 (39.7%) were unclassified (Fig. <a href="#Fig2" class="usa-link">2B</a>). In addition to the previously mentioned genes, commonly altered genes included other drivers such as <em>SMARCA4</em>, <em>KMT2D</em>, <em>CDKN2A</em>, <em>PTEN</em>, <em>ARID1A</em>, and <em>NF1</em> (Fig. <a href="#Fig2" class="usa-link">2B</a>). Targetable alterations were detected in 22 of 373 (5.9%) LCNECs and included <em>KRAS</em><sup>G12C</sup> (<em>n</em> = 13), <em>EGFR</em> activating mutations (<em>n</em> = 5), <em>ERBB2</em> mutation (<em>n</em> = 1), and fusions (<em>EML4</em>::<em>ALK</em>, <em>n</em> = 3; <em>ETV6</em>::<em>NTRK2</em>, <em>n</em> = 1).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2. Genomic blueprint of LCNECs in Cohorts 1 and 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365225_41467_2025_63091_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec1a/12365225/cec4f87dc577/41467_2025_63091_Fig2_HTML.jpg" loading="lazy" id="d33e2021" height="812" width="778" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>A</strong> CoMut plot for 85 patients with LCNEC. For each tumor, from top to bottom, the molecular subtype, sex, age at first-line systemic treatment, first-line systemic treatment, and prevalent molecular alterations. <strong>B</strong> CoMut plot for 373 patients with LCNEC. For each tumor, from top to bottom, the tumor mutational burden (mutations/Mb), LCNEC molecular subtype, sex, age, and prevalent molecular alterations. <strong>C</strong> Heatmap depicting the genomic driver and transcriptional profile evolution of two temporally different biopsies from four LCNECs in Cohort 1 and five LCNEC patients in Cohort 2<sup>*</sup>.IHC-PD-L1 (22c3) positivity ≥1<sup>†</sup>. TMB-High &gt;19 mutations (muts)/megabase (Mb). <strong>D</strong> Scatter plot showing the prevalence of genomic alterations and FDA-approved ICI biomarkers prevalence across NSCLC-like (<em>n</em> = 89) and SCLC-like (<em>n</em> = 136) LCNEC in Cohort 2. A two-sided Chi-Square test was employed with statistical significance defined as <em>p</em> &lt; 0.05. <strong>E</strong> Bar-and-whisker plot comparing FDA-approved ICI biomarkers prevalence across NSCLC-like (<em>n</em> = 89), SCLC-like (<em>n</em> = 136), and unclassified (<em>n</em> = 148) LCNECs in Cohort 2. A two-sided chi-squared test was employed with statistical significance defined as <em>p</em> &lt; 0.05. ****&lt;0.0001 (<em>p</em> value for unclassified vs NSCLC-like comparison: 000013; <em>p</em> value for unclassified vs SCLC-like comparison: 0.00002). 1L First-line, TF Transcription factor, mut mutation, dMMR Mismatch repair deficient, MSI-H microsatellite instability high, TMB Tumor mutational burden, PD-L1 Programmed death-ligand 1.</p></figcaption></figure><p id="Par13">To refine molecular classification of unclassified LCNECs, we developed a support vector machine (SVM) classifier trained on transcriptomic profiles from NSCLC-like and SCLC-like LCNEC subtypes (see “Methods”). Gene selection was guided by both high inter-sample variance and differential expression (adjusted <em>p</em> &lt; 0.01), yielding 2168 gene transcripts as input features. The model, trained on 80% of labeled samples (<em>n</em> = 174) and validated on the remaining 20% (<em>n</em> = 44), demonstrated high discriminatory performance (AUC = 0.98; accuracy = 90.1%) (Fig. <a href="#Fig3" class="usa-link">3A, B</a>). Applying the trained classifier to the 143 previously unclassified tumors, 101 (70.6%) were reclassified as SCLC-like and 42 (29.4%) as NSCLC-like. Dimensionality reduction using UMAP revealed three distinct transcriptomic clusters, with strong concordance between classifier-predicted subtypes and spatial clustering (Fig. <a href="#Fig3" class="usa-link">3C, D</a>). Notably, reclassified samples localized proximally to their respective subtype clusters, supporting the biological plausibility of the predictions. With the refined classification, we next evaluated OS and found no significant difference across the four LCNEC subtypes (log-rank <em>P</em> = 0.23, Supplementary Fig. <a href="#MOESM1" class="usa-link">7</a>).</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3. Transcriptomic modeling resolves unclassified LCNECs into NSCLC-like and SCLC-like molecular subtypes.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365225_41467_2025_63091_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec1a/12365225/f0dfb94aedad/41467_2025_63091_Fig3_HTML.jpg" loading="lazy" id="d33e2065" height="571" width="731" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>A</strong> Receiver operating characteristic (ROC) curve demonstrating the performance of a support vector machine (SVM) classifier trained to distinguish NSCLC-like from SCLC-like LCNECs based on 2168 transcriptomic features (AUC = 0.98). <strong>B</strong> Confusion matrix showing classification accuracy within the validation cohort. <strong>C</strong> Unsupervised UMAP projection of transcriptomic profiles reveals three distinct molecular clusters. <strong>D</strong> Overlay of classifier-derived labels onto the UMAP demonstrates concordance between predicted subtypes and transcriptomic clustering, enabling reclassification of previously unclassified LCNECs into biologically coherent groups. NSCLC non-small cell lung cancer, Unc Unclassified.</p></figcaption></figure><p id="Par14">To assess whether LCNECs maintain their genomic subtype over time, we analyzed data in Cohorts 1 and 2 from nine patients with two temporally distinct tumor specimens each. The median time between serial samples was 9.5 months (range 1.6–63 months) in Cohort 1 and 13 months (range 11–15 months) in Cohort 2. Our analysis revealed that the genomic drivers were consistently retained across the specimens, with no acquisition of additional genomic alterations that would reclassify the tumors. In comparison, the transcriptional subtypes exhibited greater fluidity over time, with 4 out of 5 tumor pairs demonstrating a shift in their transcriptional profiles(Fig. <a href="#Fig2" class="usa-link">2C</a>).</p>
<p id="Par15">In comparison to NSCLC-like LCNECs, <em>KMT2D</em> genomic alterations were predominantly observed in SCLC-like LCNECs, whereas <em>SMARCA4</em> alterations were more prevalent in NSCLC-like LCNECs (Fig. <a href="#Fig2" class="usa-link">2D</a>). Tumors with high tumor mutational burden (TMB-high, defined as at least 10 mutations per megabase) were found in 56.3% (<em>n</em> = 49) of NSCLC-like LCNECs and 49.6% (<em>n</em> = 67) of SCLC-like LCNECs. PD-L1 positivity (at least 1%) exhibited similar rates across the three treatment groups. Mismatch repair deficiency, determined by immunohistochemistry, was identified in 2 (1.47%) SCLC-like LCNECs (Fig. <a href="#Fig2" class="usa-link">2E</a>) and was absent in both NSCLC-like and unclassified LCNECs. There was no difference in rwPFS and OS outcomes to front-line therapy among NSCLC-like, SCLC-like, and unclassified LCNECs. Mutation analyses of key driver genes, including <em>EGFR</em>, <em>KRAS</em>, <em>KEAP1</em>, <em>RB1</em>, <em>SMARCA4</em>, and <em>STK11</em>, revealed that in Cohort 1, tumors harboring mutations in <em>TP53</em> or <em>STK11</em> were significantly associated with inferior OS compared to their wild-type counterparts (Supplementary Fig. <a href="#MOESM1" class="usa-link">8</a>). In contrast, no other genomic alterations demonstrated a statistically significant association with survival in this cohort. Similarly, in Cohort 2, none of the evaluated genomic alterations were significantly correlated with OS.</p></section><section id="Sec7"><h3 class="pmc_sec_title">LCNEC tumors are enriched for the ASCL1 and YAP1 transcriptomic subtypes</h3>
<p id="Par16">SCLCs have been classified into one of four transcriptional subtypes: ASCL1, NEUROD1, POU2F3, and YAP1 based on transcription factor (TF) expression levels<sup><a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>,<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a></sup>. We leveraged an independent cohort of 1704 SCLC from Caris Life Sciences for comparisons between SCLC and LCNECs (Supplementary Data <a href="#MOESM1" class="usa-link">6</a>). Of the 1704, 1643 SCLC had WTS data. Hierarchical clustering of 1643 SCLC and 361 LCNECs showed enrichment of ASCL1 in SCLC-like LCNEC compared with both NSCLC-like (36.56% versus 23.81%, <em>p</em> = 0.04) and unclassified (36.56% versus 11.12%, <em>p</em> &lt; 0.001, Fig. <a href="#Fig4" class="usa-link">4A</a>). The YAP1 subtype was prevalent in about 26.19% of NSCLC-like LCNECs compared to 14.18% and 31.76% of SCLC-like and unclassified LCNECs, respectively. YAP1 LCNECs were characterized by enriched CD8 infiltration as previously described for YAP1-enriched SCLC tumors<sup><a href="#CR36" class="usa-link" aria-describedby="CR36">36</a></sup> (Fig. <a href="#Fig4" class="usa-link">4B</a>, Supplementary Fig. <a href="#MOESM1" class="usa-link">9</a>). SCLC-like LCNECs were enriched for <em>STK11</em> and <em>KEAP1</em> mutations and had a significantly higher TMB compared to SCLC (Fig. <a href="#Fig4" class="usa-link">4C, D</a>). SCLC and SCLC-like LCNEC had significantly higher expression of DLL3 compared to unclassified LCNEC (SCLC vs unclassified LCNEC: median TPM = 8.3 vs 3.9, <em>p</em> &lt; 0.0001; SCLC-like LCNEC vs unclassified LCNEC: median TPM = 6.3 vs 3.9, <em>p</em> &lt; 0.05, Fig. <a href="#Fig4" class="usa-link">4E</a>). There was no significant difference in DLL3 expression between NSCLC-like and SCLC-like LCNECs. However, DLL3 expression was significantly higher in SCLC compared to NSCLC-like LCNECs (median TPM = 8.3 vs 5.7, <em>p</em> &lt; 0.05, Fig. <a href="#Fig4" class="usa-link">4E</a>).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4. Comparative analysis of transcriptional subtypes, genomic alterations, and FDA-approved ICI biomarkers in SCLC and LCNEC molecular subtypes.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365225_41467_2025_63091_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec1a/12365225/bea4aaba5db0/41467_2025_63091_Fig4_HTML.jpg" loading="lazy" id="d33e2265" height="788" width="690" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>A</strong> Heatmap illustrating hierarchical clustering of SCLC (<em>n</em> = 1643, Caris Life Sciences) and LCNECs (<em>n</em> = 361, Cohort 2) for established SCLC transcriptional subtypes (ASCL1, NEUROD1, POU2F3, and YAP1). <strong>B</strong> Bar plot showing the distribution of SCLC transcriptional subtypes across LCNECs (<em>n</em> = 361, Cohort 2). The non-parametric two-sided Wilcoxon rank sum test was used with statistical significance defined as <em>p</em> &lt; 0.05. <strong>C</strong> Comparison between the prevalence of genomic alterations and FDA-approved ICI biomarkers between SCLC (<em>n</em> = 1643, Caris Life Sciences) and SCLC-like LCNEC (<em>n</em> = 136, Cohort 2). A two-sided Chi-Square test was employed with statistical significance defined as <em>p</em> &lt; 0.05. <strong>D</strong> Bar plot illustrating the prevalence of NSCLC-like genomic drivers and FDA-approved ICI biomarkers between SCLC (<em>n</em> = 1643, Caris Life Sciences) and SCLC-like LCNEC (<em>n</em> = 136, Cohort 2). The non-parametric two-sided Wilcoxon rank sum test was used with statistical significance defined as <em>p</em> &lt; 0.05. The <em>p</em> value for <em>STK11</em> mutations was 0.003, while <em>p</em> values for both <em>KEAP1</em> mutations and tumor mutational burden (TMB) were &lt;0.0001. <strong>E</strong> Comparison of DLL3-transformed gene expression across NSCLC-like LCNEC (<em>n</em> = 84), SCLC-like LCNEC (<em>n</em> = 134), unclassified LCNEC (<em>n</em> = 143), and SCLC (<em>n</em> = 1643). The non-parametric two-sided Wilcoxon rank sum test was used with statistical significance defined as <em>p</em> &lt; 0.05. Dot plots with median values are shown. *&lt;0.05; **&lt;0.01; ****&lt;0.0001. The <em>p</em> value for unclassified versus SCLC-like LCNEC was &lt;0.0001; for unclassified versus NSCLC-like LCNEC, 0.04; and for NSCLC-like versus SCLC-like LCNEC, 0.04. dMMR Mismatch repair deficient, MSI-H microsatellite instability high, TMB Tumor mutational burden, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, LCNEC large cell neuroendocrine carcinoma.</p></figcaption></figure></section><section id="Sec8"><h3 class="pmc_sec_title">Fibrinogen-like protein 1 (FGL-1) and serine peptidase inhibitor, Kazal type 1 (SPINK1) overexpression in NSCLC-like LCNECs suggest potential therapeutic vulnerabilities</h3>
<p id="Par17">De novo differential gene expression analysis between NSCLC-like and SCLC-like LCNECs in Cohort 2 revealed substantial differences in the expression of 1061 genes (<em>p</em> &lt; 0.05, fold change &gt; 2, Fig. <a href="#Fig5" class="usa-link">5A</a>). Among these, FGL-1 and SPINK1 were markedly enriched in NSCLC-like LCNECs relative to SCLC-like LCNECs. This enrichment was characterized by ubiquitous overexpression in NSCLC-like LCNECs, in contrast to the low expression observed in other LCNEC subtypes and SCLC molecular subtypes (Fig. <a href="#Fig5" class="usa-link">5B</a>). Notably, SFTPB, a hallmark gene of type II alveolar cells, exhibited elevated expression in both NSCLC-like and unclassified LCNECs, suggesting a potentially distinct cellular origin compared to SCLC-like tumors.</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5. FGL-1 and SPINK1 are potential vulnerabilities in NSCLC-like LCNECs.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365225_41467_2025_63091_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec1a/12365225/39a2f9fb9dc6/41467_2025_63091_Fig5_HTML.jpg" loading="lazy" id="d33e2366" height="992" width="725" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>A</strong> Volcano plot showing differentially expressed genes between NSCLC-like (<em>n</em> = 89) and SCLC-like (<em>n</em> = 136) LCNECs in Cohort 2. <em>Y</em>-axis displays the −log10 <em>p</em> value derived from a two-sided Kolmogorov–Smirnov test. Genes with a False discovery rate of 5% and an absolute value of the log10 fold change of 0.5. <strong>B</strong> Heatmap of the top differentially expressed genes identified in (<strong>A</strong>), applicable to LCNEC and SCLC molecular subtypes. <strong>C</strong> Comparison of FGL-1 and SPINK1 log-transformed gene expression across LCNEC subtypes: NSCLC-like (<em>n</em> = 19), SCLC-like (<em>n</em> = 16), and unclassified (<em>n</em> = 31) LCNECs, using previously published data from George et al.<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup>. The non-parametric two-sided Wilcoxon rank sum test was used with statistical significance defined as <em>p</em> &lt; 0.05. For FGL-1, the <em>p</em> value for NSCLC-like versus SCLC-like LCNEC was 8.4 × 10<sup>−6</sup>; for NSCLC-like versus unclassified LCNEC, 0.0003; and for unclassified versus SCLC-like LCNEC, 0.01. For SPINK1, the <em>p</em> value for NSCLC-like versus SCLC-like LCNEC was 1 × 10<sup>−6</sup>; for NSCLC-like versus unclassified LCNEC, 8.3 × 10<sup>−5</sup>; and for unclassified versus SCLC-like LCNEC, 0.003. <strong>D</strong> Comparison of relative FGL-1 protein expression across 54 cell lines from various cancer types, using data from the DepMap dataset. <strong>E</strong> Box-and-whisker plots comparing median FGL-1 expression across 20 cancer types from Caris Life Sciences (<em>n</em> = 125,632 tumor samples). Dashed lines from top to bottom represent median FGL-1 expression in NSCLC-like, all, and SCLC-like LCNECs, respectively. For the box-and-whisker plots, the center line indicates the median, the bounds of the box represent the 25th and 75th percentiles (interquartile range), and the whiskers extend to the minimum and maximum values. Each point represents an individual patient tumor (biological replicate). <strong>F</strong> GSEA plots showing pathways enriched in FGL-1 high versus FGL-1 low NSCLC-like LCNECs. <strong>G</strong> Representative immunofluorescence staining of FGL-1 (green) and DAPI (white) in 2 NSCLC-like LCNECs, 1 SCLC-like LCNEC, 3 NSCLC, and 4 SCLC (<strong>H</strong>). 20× magnification is shown. The experiment was repeated using independent biological replicates (no technical replicates). Dot plot comparing tumor-infiltrating lymphocyte (TIL) counts among patients with lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), small cell lung cancer (SCLC), and large cell neuroendocrine carcinoma (LCNEC). Median values are shown per group. The non-parametric two-sided Wilcoxon rank sum test was used with statistical significance defined as <em>p</em> &lt; 0.05. TIL tumor-infiltrating lymphocytes, LUSC lung squamous cell carcinoma, LUAD lung adenocarcinoma, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, LCNEC large cell neuroendocrine carcinoma. The <em>p</em> value for SCLC versus NSCLC-like LCNEC was 0.005; for LUAD versus NSCLC-like LCNEC, 0.009; and for LUSC versus NSCLC-like LCNEC, 0.006.</p></figcaption></figure><p id="Par18">Unsupervised clustering analysis of all LCNECs, irrespective of their mutational status, delineated four distinct clusters (Supplementary Fig. <a href="#MOESM1" class="usa-link">10A</a>). Using the top differentially expressed genes between the two largest clusters (B and D, Supplementary Fig. <a href="#MOESM1" class="usa-link">10B</a>), hierarchical clustering of LCNEC samples, irrespective of molecular subtype, showed enrichment of FGL-1 and SPINK1 in cluster A, whereas FGL-1 expression was minimal in the other three LCNEC clusters (Supplementary Fig. <a href="#MOESM1" class="usa-link">10C</a>).</p>
<p id="Par19">Given the prior identification of FGL-1 as an MHC II-independent ligand for LAG-3<sup><a href="#CR37" class="usa-link" aria-describedby="CR37">37</a></sup>, we conducted further in-depth analysis to further explore this relationship within our dataset. Analysis of TCGA-LUAD data<sup><a href="#CR38" class="usa-link" aria-describedby="CR38">38</a></sup> indicated that FGL-1 expression was significantly elevated in NSCLC-like LCNEC (<em>n</em> = 6) compared to NSCLC tumors (<em>n</em> = 503, Supplementary Fig. <a href="#MOESM1" class="usa-link">11</a>). Additionally, RNA expression data from a previously published dataset of 75 LCNECs<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup> demonstrated significant enrichment of FGL-1 in NSCLC-like LCNECs (<em>n</em> = 19) compared to SCLC-like LCNECs (<em>n</em> = 16) and unclassified LCNECs (<em>n</em> = 31, Fig. <a href="#Fig5" class="usa-link">5C</a>).</p>
<p id="Par20">Examination of the DepMap dataset, encompassing 54 cell lines from various cancer types, revealed the highest protein expression of FGL-1 in the LCNEC cell line NCIH1155 (Fig. <a href="#Fig5" class="usa-link">5D</a>, Supplementary Data <a href="#MOESM5" class="usa-link">7</a>). Furthermore, WTS data from Caris Life Sciences, spanning 125,632 tumor samples across 20 cancer types, indicated that median FGL-1 expression in NSCLC-like LCNECs was the third highest, following intrahepatic cholangiocarcinoma and hepatocellular carcinoma(Fig. <a href="#Fig5" class="usa-link">5E</a>). SPINK1 shares 50% sequence homology with epidermal growth factor expression and has been shown to engage both EGFR and MAPK pathways<sup><a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>,<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a></sup>. As these are potentially targetable pathways, we leveraged the study by George et al.<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup> and showed enrichment of SPINK1 expression in NSCLC-like LCNECs compared to SCLC-like and unclassified LCNECs (Fig. <a href="#Fig5" class="usa-link">5C</a>). This observation suggests promising therapeutic strategies targeting NSCLC-like LCNECs through LAG-3 and/or SPINK1 inhibition.</p>
<p id="Par21">GSEA of Hallmark gene sets, a collection of genes curated to provide a comprehensive summary of key cellular pathways and functions<sup><a href="#CR41" class="usa-link" aria-describedby="CR41">41</a></sup>, was performed on FGL-1 high versus low NSCLC-like LCNECs. GSEA revealed, among other pathways, significant enrichment of the KRAS signaling pathway in FGL-1 high NSCLC-like tumors compared to FGL-1 low ones, suggesting a potential cross-talk between KRAS signaling and FGL-1 (Fig. <a href="#Fig5" class="usa-link">5F</a>). FGL-1 immunofluorescence staining was positive in 1 out of 2 (50%) NSCLC-like LCNEC, 0 out of 1 (0%) SCLC-like, 3 out of 3 (100%) NSCLC, and 0 out of 4 (0%) SCLC, respectively (Fig. <a href="#Fig5" class="usa-link">5G</a>).</p></section><section id="Sec9"><h3 class="pmc_sec_title">Depletion of tumor-infiltrating lymphocytes in LCNECs compared to other lung cancer cohorts</h3>
<p id="Par22">Clinical evidence suggests that the blockade of immune checkpoint pathways, such as PD-1, is most efficacious in tumors that have already initiated an endogenous T cell response. However, the observed therapeutic response in certain PD-L1–negative tumors implies that the induction of tumor rejection via PD-1 blockade does not necessarily depend on the preexistence of an immune response, as conventionally indicated by the presence of tumor-infiltrating T cells<sup><a href="#CR42" class="usa-link" aria-describedby="CR42">42</a></sup>. Given the potential for targeting alternative immune pathways through LAG-3 inhibition in NSCLC-like LCNECs, we investigated the level of immune infiltration in LCNEC tumors in comparison to SCLC and NSCLC. Employing computational pathology analysis, we quantified TILs on H&amp;E slides, following the methodology previously established by our group<sup><a href="#CR43" class="usa-link" aria-describedby="CR43">43</a></sup>. Our analysis revealed that LCNECs (<em>n</em> = 16) exhibited significantly lower TIL counts compared to lung adenocarcinomas (<em>n</em> = 353), lung squamous cell carcinomas (<em>n</em> = 63), and SCLC (<em>n</em> = 122) (Fig. <a href="#Fig4" class="usa-link">4H</a>, Supplementary Data <a href="#MOESM5" class="usa-link">8</a>). However, we were underpowered to perform analyses stratified by LCNEC molecular subtypes, as there were 6 NSCLC-like, 4 SCLC-like, and 6 unclassified LCNECs with TIL assessments.</p>
<p id="Par23">Integrating mutational subtype classification and RNA expression data leads us to propose a model that may be associated with a unique response to therapies and can be prospectively tested in clinical trials (Fig. <a href="#Fig6" class="usa-link">6</a>).</p>
<figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6. Suggested model for a therapy approach based on expression and subtypes, to be used for testing ideas in future clinical trials.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec1a/12365225/fbf6bd16ca1f/41467_2025_63091_Fig6_HTML.jpg" loading="lazy" id="d33e2495" height="280" width="634" alt="Fig. 6"></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The dashed line corresponds to a potential therapeutic target. NSCLC non-small cell lung cancer, SCLC small cell lung cancer.</p></figcaption></figure></section></section><section id="Sec10"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par24">Currently, there is no consensus on the optimal systemic treatment for LCNEC. The advent of immunotherapy has created new treatment paradigms, but comprehensive comparative analyses of first-line treatment regimens in pulmonary LCNEC are limited, particularly due to the scarcity of clinical trial data for this patient population. This gap underscores the importance of real-world studies. Our study represents the most comprehensive characterization of LCNEC to date, encompassing detailed clinical cohorts, tumor DNA sequencing, WTS, and an evaluation of the TME. Our findings reveal comparable efficacy and toxicity among patients treated with chemotherapy, chemoimmunotherapy, and immunotherapy alone. Building on existing LCNEC subtyping research, we identify therapeutic targets that have the potential to expand the treatment landscape for this aggressive malignancy, and we propose a framework to reclassify unclassified LCNECs.</p>
<p id="Par25">Recent studies in the post-front-line setting indicate that immunotherapy-based strategies may hold promise for patients with LCNEC. For instance, a retrospective study involving 23 patients treated with immunotherapy in advanced LCNEC reported a median PFS of 4.2 months<sup><a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup>. Another study, including 17 patients treated with nivolumab in the second-line setting, reported a median OS of 12.1 months and an overall response rate of 29.4%, with a median PFS of 3.9 months<sup><a href="#CR44" class="usa-link" aria-describedby="CR44">44</a></sup>. Our analysis did not reveal significant differences in OS outcomes across various treatment groups, including immunotherapy-based regimens. There was a statistically significantly lower rwPFS for patients treated with chemotherapy compared to chemoimmunotherapy, although the difference was not clinically significant (median rwPFS difference of 0.3 months). In general, patients exhibited typical poor outcomes regardless of the systemic treatment regimen employed.</p>
<p id="Par26">Genomic analysis from our study revealed that close to 6% of LCNEC possess targetable genomic alterations amenable to existing FDA-approved therapies for lung cancer, corroborating previous findings, and supporting the use of WES in this patient population at the time of diagnosis<sup><a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>,<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a></sup>. Previous studies have classified LCNEC into genomic subtypes paralleling either SCLC or NSCLC<sup><a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>,<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>,<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup>. In the vast majority of patients lacking targetable driver mutations, our results demonstrate that current systemic treatments do not significantly enhance clinical outcomes across these genomic subtypes. Notably, our data indicate that patients with NSCLC-like LCNECs exhibit elevated expression of FGL-1 and SPINK1 at the RNA level with variable protein expression of FGL-1, suggesting potential therapeutic benefits from targeting LAG-3 or SPINK1 pathways. This emphasizes the critical need for clinical trials investigating LAG-3 inhibitors or FGL-1 antibody-drug conjugates in this context. Furthermore, SPINK1-positive cancers could potentially benefit from interventions targeting downstream effectors such as the MAPK pathway<sup><a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>–<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a></sup>. While our study primarily focuses on the molecular and clinical characterization of LCNEC, the functional significance of FGL-1 and SPINK1 remains unresolved. Future in vitro and in vivo studies are warranted to elucidate its role in tumor progression and immune evasion, which may further support its development as a therapeutic target.</p>
<p id="Par27">SCLC-like and NSCLC-like LCNECs exhibit elevated DLL3 expression, suggesting that DLL3 antibody-drug conjugates or bispecific antibodies, or T cell engagers, may provide a promising therapeutic approach for targeting these tumors in a manner analogous to SCLC<sup><a href="#CR49" class="usa-link" aria-describedby="CR49">49</a></sup>. Ongoing clinical trials (<a href="https://clinicaltrials.gov/ct2/show/NCT05882058" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05882058</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT05619744" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05619744</a>) are actively investigating DLL3-targeted therapies in patients with LCNEC. We also utilized digital assessment of TILs to show a significant reduction of TILs in LCNECs compared to other lung cancer types. The low absolute levels of TILs in LCNECs could suggest that these tumors are either altered or cold immune tumors, potentially explaining the modest efficacy of immunotherapy-based approaches observed so far. Overall, these findings underscore the urgent requirement for innovative clinical trials and the exploration of therapeutic strategies to improve outcomes for patients with LCNEC.</p>
<p id="Par28">A key contribution of our study is the resolution of previously unclassified LCNECs through integrative transcriptomic modeling. Utilizing an SVM classifier trained on NSCLC-like and SCLC-like subtypes, we reclassified the majority of unclassified tumors into biologically coherent groups with high discriminatory performance (AUC = 0.98). This refined molecular taxonomy offers a critical framework for aligning LCNEC subtypes with targeted therapeutic strategies. Nonetheless, prospective validation in independent cohorts is warranted to confirm the robustness and clinical applicability of this reclassification schema.</p>
<p id="Par29">Recent studies in SCLC have questioned the existence of a YAP1-defined subtype, as immunohistochemical and molecular profiling analyses failed to confirm its distinction within SCLC<sup><a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>,<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a></sup>. However, emerging evidence suggests that YAP1 plays a biologically significant role in pulmonary LCNEC. In our cohort, YAP1 subtypes were found in more than a quarter of NSCLC-like, SCLC-like, and unclassified LCNECs. A recent study also demonstrated that YAP1 expression defines two intrinsic subtypes of LCNEC with distinct molecular characteristics and therapeutic vulnerabilities<sup><a href="#CR52" class="usa-link" aria-describedby="CR52">52</a></sup>. The YAP1-high subtype is associated with a mesenchymal and inflamed phenotype, frequent <em>SMARCA4</em> and <em>CDKN2A/B</em> genomic alterations, and vulnerability to MEK and AXL-targeted therapies. In contrast, the YAP1-low subtype shares genomic and transcriptomic similarities with SCLC, including <em>RB1</em> and <em>TP53</em> co-mutations, a neuroendocrine phenotype, and potential susceptibility to SCLC-directed therapies, such as DLL3 and CD56-targeting CAR T therapies. These findings underscore the biological significance of YAP1 in LCNEC and highlight its potential role in guiding therapeutic strategies. Future research should further investigate whether YAP1 expression influences tumor plasticity, immune microenvironment interactions, and treatment response, particularly in the context of emerging therapies for LCNEC.</p>
<p id="Par30">Our study has several limitations that warrant consideration. First, the retrospective design inherently introduces biases and limits the ability to draw causal inferences. Second, the clinical data were incomplete, and follow-up intervals were not standardized, potentially introducing variability in the calculation of rwPFS. Moreover, the retrospective nature of the study introduces variability in treatment decisions based on evolving clinical guidelines and physician discretion. While PD-L1 expression and TMB were assessed where available, additional factors such as histologic subtype, prior treatment history, and disease burden also influenced therapy initiation. However, due to the lack of standardized prospective selection criteria, we cannot fully account for all variables that may have guided immunotherapy decisions. Overall, these limitations reflect the inherent heterogeneity of real-world data collection and may affect the robustness of rwPFS estimates. As such, we emphasize the need for prospective studies to validate and build upon our findings, thereby enhancing their translational potential. Third, in Cohort 1, the use of variable targeted sequencing platforms to identify mutations and copy number alterations posed a challenge. Differences in gene composition and baitset coverage across these platforms limited the comprehensiveness of genomic analyses. To overcome this limitation, we included Cohort 2, which underwent systematic and uniform genomic and transcriptomic characterization, thereby providing a more consistent and robust dataset of equivalent size. Fourth, matched germline testing was not uniformly available across sequencing platforms, and this limitation was further compounded by variability in germline filtering algorithms. These factors may influence the interpretation of mutational drivers and TMB estimates. While this may have led to occasional false-positive somatic calls, it reflects current practice across CLIA-certified platforms, which largely rely on tumor-only sequencing and population databases for germline exclusion. Fifth, the study lacked detailed information on the specific biopsy methods used for diagnosing LCNEC. This limitation may impact the interpretation of diagnostic challenges associated with small biopsy specimens; however, all cases were reviewed and confirmed by board-certified thoracic pathologists. Sixth, our study is limited by the under-representation of non-White populations, which reduces the generalizability of our findings and limits the statistical power to identify genomic and survival associations within these subgroups. This highlights the critical need for more inclusive research to ensure findings are applicable across diverse patient populations. Moreover, in Cohort 1, LCNEC diagnoses were made by local pathologists without centralized pathological review, raising the possibility of case overestimation and inadvertent inclusion of tumors with mixed histologic features. However, a validation study conducted by Caris Life Sciences on a subset of samples initially classified as LCNEC revealed that 95% of these cases were confirmed upon central pathological review, supporting the accuracy of the classifications. Additionally, the use of FFPE material introduces the potential for sequencing artifacts, although standardized quality control measures were employed to minimize this risk. Finally, given the rarity of LCNEC, we extended the study period to accumulate a sufficiently large sample size. This approach, while necessary, may have introduced variability in the reliability of estimates when comparing treatment strategies due to temporal trends. To account for this, sensitivity analyses stratified by treatment year were conducted to evaluate potential temporal influences.</p>
<p id="Par31">Despite these limitations, our analyses consistently revealed similar clinical outcomes across the two distinct cohorts, underscoring the robustness of our findings. The complementary nature of these datasets allowed us to capture a broader spectrum of clinical and molecular characteristics of LCNEC, leveraging the unique strengths of each cohort to provide a more comprehensive understanding of this rare malignancy. By analyzing the cohorts independently for most outcomes, we effectively mitigated the confounding effects of methodological differences, ensuring the integrity of our results. Collectively, the two cohorts represent the most extensive and integrative analysis of LCNEC to date, offering critical insights into its genomic landscapes and clinical behavior, and paving the way for future research and therapeutic innovations.</p>
<p id="Par32">In conclusion, while the systemic treatment of LCNEC remains an area of unmet clinical need, our study advances the field by offering the most extensive and integrative analysis of this malignancy to date. Through meticulous examination of clinical outcomes, genomic landscapes, and the TME, we illuminate the complexity of LCNEC and highlight critical avenues for therapeutic intervention. Our findings challenge the efficacy of current systemic therapies across LCNEC subtypes, underscoring the urgent need for treatment strategies tailored to the molecular underpinnings of this aggressive cancer. The identification of actionable targets such as FGL-1, SPINK1, and DLL3 opens new frontiers in LCNEC therapy, with ongoing clinical trials poised to transform the treatment landscape. However, the modest responses to immunotherapy observed in our study and the paucity of TILs in LCNEC tumors suggest that future efforts must also focus on overcoming immune evasion mechanisms. To truly shift the paradigm in LCNEC treatment, it will be imperative to conduct robust, prospective clinical trials that not only evaluate the efficacy of emerging therapies but also ensure inclusivity across diverse patient populations.</p></section><section id="Sec11"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec12"><h3 class="pmc_sec_title">Patient cohorts</h3>
<p id="Par33">To provide a broad description of treatment patterns in patients with LCNEC, we gathered data from two large historical cohorts: Cohort 1 is a multicenter study of 217 patients with LCNEC treated with 1st line systemic treatment between 1/2014 and 12/2023. Clinical information was gathered from 26 participating institutions in Belgium, Germany, Italy, Spain, the United Kingdom, and the United States (Supplementary Data <a href="#MOESM5" class="usa-link">1</a>). This study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Yale New Haven Hospital Institutional Review Board (IRB) as well as the IRBs of the respective participating institutions. Although the study relied exclusively on de-identified data, we acknowledge that genetic data, while de-identified, retains inherent identifiability due to its unique nature. In compliance with HIPAA guidelines and considering GDPR classifications of genetic data as personal data, stringent safeguards were implemented to protect patient confidentiality. No direct identifiers were accessible to study investigators, and data were managed within secure, access-controlled environments. Based on the use of de-identified data and the minimal risk posed to participants, written informed consent was waived by the IRBs. For Cohort 1, the pathologic diagnosis of LCNEC was reviewed at the local treating institution and confirmed by pulmonary pathologists according to the 5th edition of the WHO Classification of Lung Tumors<sup><a href="#CR53" class="usa-link" aria-describedby="CR53">53</a></sup>. The diagnosis of pulmonary LCNEC required the presence of neuroendocrine morphology (organoid nesting, palisading, rosettes, or trabeculae) and expression of at least one neuroendocrine marker (chromogranin A, synaptophysin, INSM1, CD56) by immunohistochemistry. High mitotic activity (&gt;10 mitoses per 2 mm²) and/or extensive necrosis were also required for classification. Tumor specimens with mixed histologic components (adenocarcinoma, squamous cell carcinoma, or SCLC) other than LCNEC were excluded to enrich for LCNECs.</p>
<p id="Par34">Cohort 2 represents a historical cohort collected by Caris Life Sciences (Phoenix, AZ, USA) between 1/2015 and 11/2023. This included 373 patients diagnosed with LCNEC who underwent tissue-based genomic profiling by a commercial laboratory (Caris Life Sciences). The specimens were primarily composed of diagnostic biopsy or surgical tumor samples. Of these, a subset of 146 patients met the inclusion criteria for clinical outcome analyses, consistent with Cohort 1, defined as having advanced LCNEC treated with first-line systemic therapies. This focus was driven by the study’s objective to investigate first-line treatment outcomes in advanced LCNEC—a critical and understudied area in the field. The remaining patients, who either did not have advanced LCNEC or were not treated with first-line systemic therapies, were excluded from the clinical outcome analyses but included in genomic and transcriptomic correlates. This approach ensured alignment with the study’s objectives to investigate the treatment landscape and outcomes for advanced LCNEC. Clinical data were acquired from insurance claims, and the selection of systemic therapies was at the discretion of the treating physician. The sex and age of patients were determined from medical forms. For Cohort 2, pathologic diagnosis was initially confirmed at local institutions and later reviewed centrally at Caris Life Sciences for accuracy in a subset of 142 tumors with a diagnostic accuracy rate of 94.3%. Systemic treatments for both cohorts included chemotherapy alone, chemoimmunotherapy, and immunotherapy alone. An independent cohort of 1704 SCLCs from Caris Life Sciences was utilized for comparison with LCNECs.</p></section><section id="Sec13"><h3 class="pmc_sec_title">Genetic analysis</h3>
<p id="Par35">In Cohort 1, local institutions utilized standard-of-care genomic sequencing platforms to identify mutations and copy number alterations in key oncogenic drivers, including <em>ALK</em>, <em>EGFR</em>, <em>KEAP1</em>, <em>KRAS</em>, <em>MET</em>, <em>RB1</em>, <em>SMARCA4</em>, <em>STK11</em>, and <em>TP53</em>. The use of institution-specific platforms introduced variability in gene coverage and analytical methodologies but reflects the diversity inherent in clinical practice.</p>
<p id="Par36">In Cohort 2, a more standardized approach was employed. Tumor samples underwent microdissection prior to nucleic acid isolation to enrich for tumor content. Next-generation sequencing (NGS) was then conducted on genomic DNA using either the NextSeq platform (Illumina, Inc., San Diego, CA, USA) for a targeted panel of 592 cancer-relevant genes (<em>n</em> = 84 samples) or the Illumina NovaSeq 6000 platform (Illumina, Inc., San Diego, CA, USA) for WES (<em>n</em> = 289 samples). For NextSeq-sequenced tumors, a custom-designed SureSelect XT assay (Agilent Technologies, Santa Clara, CA, USA) was employed to enrich for the 592 target genes. For NovaSeq-sequenced tumors, a hybrid pull-down panel of baits was used to achieve high coverage and read depth for &gt;700 clinically relevant genes (average 500×), with additional enrichment for &gt;20,000 genes at an average depth of 200x. Genetic variants were detected with &gt;99% confidence and classified by board-certified molecular geneticists using previously established criteria<sup><a href="#CR54" class="usa-link" aria-describedby="CR54">54</a></sup>.</p>
<p id="Par37">These methodological differences between Cohorts 1 and 2 highlight the real-world heterogeneity in clinical and genomic data acquisition. To ensure scientific rigor, analyses were conducted separately where appropriate, accounting for the inherent differences in data generation and processing between the two cohorts.</p></section><section id="Sec14"><h3 class="pmc_sec_title">Variant assessment</h3>
<p id="Par38">For Cohort 1, variants assumed to be oncogenic or likely oncogenic on OncoKB were considered pathogenic<sup><a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>,<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a></sup>. For Cohort 2, genomic alterations were reviewed by board-certified clinical geneticists according to criteria established by the American College of Medical Genetics and Genomics<sup><a href="#CR57" class="usa-link" aria-describedby="CR57">57</a></sup>.</p></section><section id="Sec15"><h3 class="pmc_sec_title">RNA sequencing</h3>
<p id="Par39">We obtained publicly available RNA WTS data from The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) data collection (<em>n</em> = 515 tumors)<sup><a href="#CR38" class="usa-link" aria-describedby="CR38">38</a></sup>. For each specimen, the normalized transcripts-per-million (TPM) counts were calculated, and the data were log2 transformed. Gene set enrichment analysis (GSEA <a href="http://software.broadinstitute.org/gsea/index.jsp" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://software.broadinstitute.org/gsea/index.jsp</a>) was performed using the clusterProfiler package (version 4.12.2) in R (version 4.4.1), with hallmark gene sets from the Molecular Signatures Database (MSigDB v2023.2).</p>
<p id="Par40">For Cohort 2, RNA WTS was conducted using a hybrid-capture approach from formalin-fixed paraffin-embedded (FFPE) tumor samples (<em>n</em> = 373) with the Agilent SureSelect Human All Exon V7 bait panel (Agilent Technologies; RRID) and the Illumina NovaSeq platform (Illumina, Inc.). Pathology review of FFPE specimens was performed to determine the percent tumor content and tumor size, requiring at least 20% tumor content in the area for microdissection to allow for enrichment and extraction of tumor-specific RNA. Extraction was carried out using a Qiagen RNA FFPE Tissue Extraction Kit, and the RNA quality and quantity were assessed with the Agilent TapeStation. Biotinylated RNA baits were hybridized to the synthesized and purified cDNA targets, followed by a post-capture PCR amplification of the bait-target complexes. The resulting libraries were quantified, normalized, pooled, denatured, diluted, and sequenced. Raw data were demultiplexed using the Illumina DRAGEN FFPE accelerator. Briefly, FASTQ files were aligned with the STAR aligner (Alex Dobin, release 2.7.4a, GitHub, <a href="https://github.com/alexdobin/STAR/releases/tag/2.7.4a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://github.com/alexdobin/STAR/releases/tag/2.7.4a</a>). A complete 22,948-gene dataset of expression data was generated by Salmon, which offers fast and bias-aware quantification of transcript expression<sup><a href="#CR58" class="usa-link" aria-describedby="CR58">58</a></sup>. BAM files from the STAR aligner (RRID: SCR_004463) were further processed for RNA variants using a proprietary custom detection pipeline. The reference genome used was GRCh37/hg19, and analytical validation of this test showed ≥97% positive percent agreement, ≥99% negative percent agreement, and ≥99% overall percent agreement with a validated comparator method.</p>
<p id="Par41">Immune cell fractions within the tumor microenvironments (TMEs) were estimated by deconvoluting RNA expression profiles using quanTIseq (RRID:SCR_022993)<sup><a href="#CR59" class="usa-link" aria-describedby="CR59">59</a></sup>. QuanTIseq is a computational tool that quantifies the abundance of ten immune cell populations from WTS. The algorithm is validated against flow cytometry and immunohistochemistry for determining the absolute fractions of myeloid dendritic cells, regulatory T cells (Tregs), CD8+ and CD4+ T cells, natural killer (NK) cells, neutrophils, monocytes, M1 and M2 macrophages, and B cells.</p></section><section id="Sec16"><h3 class="pmc_sec_title">Immunohistochemistry for PD-L1 status and immunofluorescence for FGL-1</h3>
<p id="Par42">For Cohort 1, PD-L1 status was determined using one of the following anti-PD-L1 antibodies: 22c3, 28-8 (Agilent, Dako), and SP263 (Ventana). For Cohort 2, PD-L1 status was determined using the 22c3 anti-PD-L1 antibody (Dako) on FFPE sections. The evaluation involved calculating the percentage of positively stained tumor cells to obtain a tumor proportion score<sup><a href="#CR60" class="usa-link" aria-describedby="CR60">60</a></sup>.</p>
<p id="Par43">For FGL-1 immunofluorescence, tumor regions from paraffin-embedded sections were delineated by a board-certified pathologist using corresponding hematoxylin and eosin (H&amp;E)-stained slides. Unstained FFPE slides from NSCLC-like LCNEC (<em>n</em> = 2), SCLC-like LCNEC (<em>n</em> = 1), NSCLC (<em>n</em> = 3), and SCLC (<em>n</em> = 4) were immersed in Xylene I/II, absolute ethyl alcohol, 95% and 85% alcohol to deparaffinize the tissue sections. The slides were then subjected to antigen retrieval using Tris-EDTA buffer (pH = 8.0) at 98 °C for 20 min. Slides were blocked with 1% BSA, 4% Horse Serum, 0.4% Triton-X100 in PBS for 30 min, then incubated overnight at 4 °C with an anti-FGL-1 rabbit polyclonal primary antibody (Proteintech, 16000-1-AP) mouse monoclonal primary antibody (Proteintech, 66483-1-Ig) at 1:200. An anti-rabbit corresponding secondary antibody was used at a 1:1000 dilution, for 2 h at room temperature. Sections were then mounted with Fluoroshield histology medium containing DAPI (Sigma, F6057). Confocal imaging was acquired with an LSM880 microscope with Airyscan, and data were analyzed by using ImageJ.</p></section><section id="Sec17"><h3 class="pmc_sec_title">Digital pathology assessment of tumor-infiltrating lymphocytes</h3>
<p id="Par44">For DFCI lung tumor samples, H&amp;E slides were digitized using the Aperio AT at a resolution of 0.49 microns per pixel. The detailed method is reported previously<sup><a href="#CR43" class="usa-link" aria-describedby="CR43">43</a></sup>. Briefly, the images were processed in QuPath (v.4.0) using built-in functions. This involved color deconvolution to estimate stain vectors and normalize the RGB channels for each image. For cell detection, watershed segmentation was employed to identify cells based on size, shape, and the optical density of nuclei in the hematoxylin channel. Additional features were calculated by adding intensity and smoothed object features, computing Haralick texture features, and determining Gaussian-weighted averages per object/cell. A random forest algorithm was used to train an object classifier to identify tumor-infiltrating lymphocytes (TILs), tumor cells, and stromal cells. TILs were defined as mononuclear immune cells, including lymphocytes and plasma cells.</p></section><section id="Sec18"><h3 class="pmc_sec_title">Mismatch repair status</h3>
<p id="Par45">Multiple test platforms were used to determine the MSI or MMR status. These included fragment analysis (MSI Analysis System kit; Promega, Madison, WI, USA), immunohistochemistry staining (MLH1, M1 antibody; MSH2, G2191129 antibody; MSH6, 44 antibody; and PMS2, EPR3947 antibody; Ventana Medical Systems, Tucson, AZ, USA), and NGS (examining 7000 target microsatellite loci and comparing them to the reference genome hg19 from the University of California Santa Cruz (UCSC) Genome Browser database). The results from these three platforms were highly concordant. In rare cases of discordant results, the microsatellite stability or MMR status of the tumor was determined in the order of immunohistochemistry, fragment analysis, and NGS<sup><a href="#CR61" class="usa-link" aria-describedby="CR61">61</a></sup>.</p></section><section id="Sec19"><h3 class="pmc_sec_title">Tumor mutational burden</h3>
<p id="Par46">In Cohort 2, tumor mutational burden (TMB) was assessed by counting all nonsynonymous missense, nonsense, in-frame insertion/deletion, and frameshift mutations in each tumor that were not previously identified as germline alterations in dbSNP151, the Genome Aggregation Database (gnomAD), or as benign variants by Caris’s geneticists. TMB-High was defined as having &gt;19 mutations per megabase (muts/Mb), in accordance with the KEYNOTE-158 pembrolizumab trial<sup><a href="#CR62" class="usa-link" aria-describedby="CR62">62</a></sup>.</p></section><section id="Sec20"><h3 class="pmc_sec_title">Statistical analyses</h3>
<p id="Par47">For Cohorts 1 and 2, no statistical method was used to predetermine the sample size. To ensure robust analyses and minimize confounding due to cohort-specific biases, clinical outcomes were analyzed separately for Cohorts 1 and 2. Overall survival (OS) in the ICI cohort was calculated from the time of first anti-PD-1/L1 drug treatment (pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, or cemiplimab) to death or last follow-up. OS in the chemotherapy and chemoimmunotherapy cohorts was calculated from the time of the first systemic treatment to death or last follow-up. Real-world progression-free survival (rwPFS) was calculated from the date of initiation of first-line systemic therapy to the date of progression or death. Disease progression was determined based on available clinical records, imaging studies, or treating physician assessments, as documented in patient charts or claims data. Alive patients were censored at the date of last follow-up. Time on treatment (ToT) was calculated from the start date of first-line systemic therapy to the end date. Patients who were still alive and receiving ongoing treatment were censored at the date of their last follow-up. Survival functions were estimated using the Kaplan–Meier method, and survival distributions were compared using a two-sided log-rank test. <em>P</em> values less than 0.05 were considered significant. Multivariable Cox proportional hazards regression models for rwPFS and OS were performed and adjusted for variables selected a priori: Sex, ECOG performance status, age at time of systemic treatment, and M stage (M1a, M1b, M1c). For the analysis of TME biomarkers and GSEA, a false discovery rate of 0.05, determined by the Benjamini–Hochberg procedure, was used to define statistical significance. Median follow-up time was determined by the reverse Kaplan–Meier method. Analyses were conducted using Python 3.12.5 and RStudio 2024.04.2 + 764.pro1.</p></section><section id="Sec21"><h3 class="pmc_sec_title">Reporting summary</h3>
<p id="Par48">Further information on research design is available in the <a href="#MOESM3" class="usa-link">Nature Portfolio Reporting Summary</a> linked to this article.</p></section></section><section id="Sec22"><h2 class="pmc_sec_title">Supplementary information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supplementary information</a><sup> (2.1MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM2_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Peer review</a><sup> (65.1KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM3_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Reporting Summary</a><sup> (101.6KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM4"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM4_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">41467_2025_63091_MOESM4_ESM.pdf</a><sup> (6.3KB, pdf) </sup><p>Description of Additional Supplementary Files</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM5"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM5_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Data 1–8</a><sup> (4.9MB, xlsx) </sup>
</div></div></section></section><section id="Sec23"><h2 class="pmc_sec_title">Source data</h2>
<section class="sm xbox font-sm" id="MOESM6"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM6_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Source data</a><sup> (119.8MB, xlsx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>D.J.P. acknowledges grant support from the UKRI IAA Healthy Society Grant Scheme (Round 2023), the Cancer Treatment and Research Trust (CTRT), and infrastructural support by the Imperial Experimental Cancer Medicine Centre and the NIHR Imperial Biomedical Research Centre.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Conceptualization: A.H.N., C.K., A.R.N., A.C.C. Data curation: A.H.N., T.A., E.B.F., H.A., M.R., K.M., S.F.L., Y.T., A.O., F.A.L., T.L., S.R., S.A., J.E.G., J.H., D.K., J.B., M.Z.B., F.A.N., C.G., H.L., F.C., A.C., E.C.M., D.P., M.D., T.J.E.C., J.M.C., J.J.L., A.S.W., D.R.C., A.S., K.P., F.Cro., T.U.M., V.A., M.Ah., K.S., H.Kw., J.Z., D.H.O., M.L. (Mingjia Li), M.N., D.J.P., N.A., K.A., S.P., U.Z., D.M.G., C.L., H.K., J.Lia., A.I.V., T.B., L.M., M.M., P.R., M.E., A.V., A.E., J.N., G.L., P.C.M., H.B., M.L2. (Matthew Lee), L.Y., R.A., H.M., D.J.K., R.S.H., R.A.F., A.R.N., A.C.C. Formal analysis: A.H.N., T.A., H.A. Funding acquisition: none. Investigation: A.H.N., C.K., A.R.N., A.C.C. Methodology: A.H.N., C.K., T.A., A.R.N., A.C.C. Project administration: A.H.N., T.A., A.R.N., A.C.C. Resources: A.H.N., C.K., A.R.N., A.C.C. Supervision: A.H.N., A.R.N., A.C.C. Validation: not applicable. Visualization: A.H.N., T.A., H.A. Writing—original draft: A.H.N., C.K., A.R.N., A.C.C., H.A. Writing—review and editing: All authors listed under data curation.</p></section><section id="notes2"><h2 class="pmc_sec_title">Peer review</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Peer review information</h3>
<p id="Par49"><em>Nature Communications</em> thanks Shigeki Umemura and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.</p></section></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>Raw sequencing data for Figs. <a href="#Fig1" class="usa-link">1b</a>, <a href="#Fig2" class="usa-link">2b–e</a>, <a href="#Fig3" class="usa-link">3</a>, <a href="#Fig4" class="usa-link">4</a> and <a href="#Fig5" class="usa-link">5a, b</a> were generated by Caris Life Sciences and are not publicly available due to patient privacy concerns and proprietary restrictions. These data are considered third-party clinical datasets and are owned by Caris Life Sciences. Access is restricted due to legal and privacy protections. Raw data cannot be deposited in a public repository. Aggregated and de-identified data may be made available for academic research purposes upon request. Researchers should contact the corresponding author with a brief description of the data required and the intended use. All requests will be reviewed by the Caris data access team, and a response will be provided within 4 weeks. Once access is granted, data will remain available for the duration of the agreed-upon research project, subject to compliance with Caris Life Sciences’ data use agreement. External datasets used in this study are publicly available<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>,<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a></sup>. All other data supporting the findings of this study, including source data underlying the figures and tables (excluding the Caris-derived panels), are provided in the accompanying Source data file. <a href="#Sec23" class="usa-link">Source data</a> are provided with this paper.</p></section><section id="FPar2"><h2 class="pmc_sec_title">Competing interests</h2>
<p id="Par50">A.H.N.: honoraria: the Korean Society of Medical Oncology, TEMPUS, OncLive, Oklahoma University, Targeted Oncology; travel compensation: Korean Society of Medical Oncology, American Association for Cancer Research; consultation fees: Guidepoint Global, Putnam Associates, Capvision; compensation from Outlier.ai to provide feedback on data analysis tools, AI development; Equity in Revolution Medicine, Summit Therapeutics. M.G.E. receives full-time employment, travel/speaking expenses, and stock/stock options from Caris Life Sciences. A.C.C.: advisory boards: AbbVie, Amgen, BI, Merck, Jazz, and Research funding: Zai Labs. D.J.P.: Lecture fees: Bayer Healthcare, AstraZeneca, EISAI, Bristol Myers Squibb, Roche, Ipsen, OncLive; Travel expenses: Bristol Myers Squibb, Roche, Bayer Healthcare; Consulting fees: Mina Therapeutics, Boeringer Ingelheim, Ewopharma, EISAI, Ipsen, Roche, H3B, AstraZeneca, DaVolterra, Starpharma, Boston Scientific, Mursla, Avammune Therapeutics, LiFT Biosciences, Exact Sciences; Research funding (to institution): MSD, BMS, GSK, EISAI. N.A.: No conflicts to declare. P.R. reports travel support from AstraZeneca, MSD, BMS, and Kiowa Kirin outside the submitted work. M.R. received lecture fees from AstraZeneca. F.A.-L.: Research PI (AZ, Alira Health). A.I.V. received consulting honorarium from AstraZeneca, AbbVie, Janssen, Regeneron, Merus, and Novocure. T.A.: Employee of Caris Life Sciences. J.Z. reported the following: Grants/Contracts: AbbVie, AstraZeneca, BeiGene, BridgeBio, Genentech, Hengrui Therapeutics, InnoCare Pharma, Janssen, Kahr Medical, Merck, Mirati Therapeutics, Nilogen, Novartis, Champions Oncology, BMS. Consulting fees: AstraZeneca, Hengrui Therapeutics, Mirati Therapeutics, Novartis, Novocure, Regeneron, Sanofi, and Takeda Oncology. Payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or educational events: AstraZeneca, MJH Life Sciences, Novartis, Regeneron, Sanofi, and Takeda. A.S.W. has performed consulting work for MJH Life Sciences and received speaking fees from The Binaytara Foundation and Janssen. L.M.: Travel support: BMS. J.B.: grants for consultancies/advisory boards: BMS, Roche, AstraZeneca. Speaker fees: AstraZeneca, Lilly, Johnson and Johnson. Travel support: Roche, AstraZeneca, MSD, Johnson and Johnson. Research funding (to institution): SEOM. C.G.: grants for consultancies/advisory boards: MSD, BMS, Oncowissen, AstraZeneca, REGENERON, Roche. Speaker fees: AstraZeneca, Boehringer Ingelheim, Chugai, Pierre-Fabre, MSD, Sanofi/REGENERON. Writing/Editorial activity: BMS, MSD. Travel support: Sanofi/REGENERON, MSD. Research fundings (to institution): BMBF/Deutsche Krebshilfe/Deutsche Forschungsgemeinschaft. D.O.: Honorarium: Chugai. Research funding (to institution): Merck, BMS, Palobiofarma, Genentech, AbbVie, Nuvalent, Onc.AI. J.K.H. received consulting honorarium from Jackson Laboratory for Genomic Medicine and ARUP. H.B.: Research Support (Clinical Trials): BMS, Lilly, Amgen; Advisory Board/Consultant: BMS, Lilly, Genentech, Pfizer, Merck, EMD Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Puma, BerGenBio, Bayer, Iobiotech, Grid Therapeutics, RAPT; Data and Safety Monitoring Board: University of Pennsylvania: CAR T Program, Takeda, Incyte, Novartis, Springworks; Scientific Advisory Board: Sonnetbio (Stock Options); Inspirna (formerly Rgenix, Stock Options); Nucleai (stock options); Honoraria: Amgen, Pfizer, Daiichi, Regeneron; Travel: Amgen, BMS, Merck, Lilly, EMD Serono, Genentech, Regeneron, Mirati. M.D.: Advisory boards; Sanofi/Genzyme, Regeneron, Janssen, AstraZeneca, Gilead, Bristol Myer Squibb, Catalyst Pharmaceuticals, Novocure, Guardant Consulting: AbbVie, Janssen, Gilead, Daiichi Sankyo, Bristol Myer Squibb Research: Merck, Genentech, CellSight, Novartis, Varian. A.E.: Employee of Caris Life Sciences. J.J.L. has served as a compensated consultant for Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, AnHeart Therapeutics, Takeda, CLaiM Therapeutics, Ellipses, Hyku BioSciences, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Yuhan, Merus, Regeneron, Pfizer, Nuvation Bio, and Turning Point Therapeutics; has received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, Linnaeus Therapeutics, Nuvalent, and Novartis; and travel support from Pfizer and Merus. C.K.: Research funding (to institution): AstraZeneca, Novartis, Regeneron, Janssen, Genentech, Lyell, Daiichi Sankyo, Gilead, Macrogenics, Boehringer Ingelheim, Black Diamond Therapeutics. Consulting fees: Arcus, AstraZeneca, Daiichi Sankyo, Eisai, Regeneron, Sanofi, Takeda, J&amp;J, Pinetree, Boehringer Ingelheim, Gencurix. M.N. is on the advisory board for AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Janssen, Pfizer, Eli Lilly and Company, Bayer, Regeneron, BMS and Genentech; consultant for Caris Life Sciences (virtual tumor board); speaker for Blueprint Medicines, Janssen, Mirati and Takeda; and reports travel support from AnHeart Therapeutics. Reports stock/stock options from MBrace Therapeutics. T.U.M. currently or has previously served on Advisory and/or Data Safety Monitoring Boards for Rockefeller University, Regeneron, AbbVie, Merck, EMD Serono, Storm, Geneos, Bristol-Meyers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, DrenBio, Glenmark, Simcere, Arrowhead, Surface/Coherus, G1 Therapeutics, NGMbio, DBV Technologies, Arcus, Fate, Ono, Storm, Replimmune, Larkspur, Avammune, and Astellas, and has research grants from the National Institutes of Health (NCI), the Cancer Research Institute, Regeneron, Genentech, Bristol Myers Squibb, Merck, and Boehringer Ingelheim. A.R.N. reports: Funding to Institution for Trials he is PI on: Loxo@Lilly, Surface Oncology, ADC Therapeutics, IGM Biosciences, EMD Serono, Aravive, Nikang Therapeutics, Inspirna, Exelexis, Revolution Medicine, Jacobio, Pionyr, Jazz Pharmaceuticals, NGM Biopharmaceuticals, Immunocore, Phanes Therapeutics, Kymera Therapeutics, Dren Bio, Daichi; Consultant Editor Compensation: JCO Precision Oncology; Travel Compensation from: SITC/ AACR/ Conquer Cancer Foundation/BinayTara Foundation and Foundation Med/ Caris Life Sciences/ ASCO; Advisory Board: Foundation Med, Astellas, NGM biosciences, Natera, Regeneron; Honoraria: BinayTara Foundation, Foundation Med, Medlive; Grant Support: SOWG Hope Foundation. The remaining authors declare no competing interests.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1"><p><strong>Publisher’s note</strong> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>
<div class="fn p" id="fn2"><p>These authors contributed equally: Amin H. Nassar, Chul Kim.</p></div>
<div class="fn p" id="fn3"><p>These authors jointly supervised this work: Abdul Rafeh Naqash, Anne C. Chiang.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Abdul Rafeh Naqash, Email: abdulrafeh-naqash@ou.edu.</p>
<p>Anne C. Chiang, Email: anne.chiang@yale.edu</p></section><section id="sec24"><h2 class="pmc_sec_title">Supplementary information</h2>
<p>The online version contains supplementary material available at 10.1038/s41467-025-63091-0.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Travis, W. D. et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. <em>J. Thorac. Oncol.</em><strong>10</strong>, 1243–1260 (2015).
</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000630" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26291008/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Travis,%20W.%20D.%20et%20al.%20The%202015%20World%20Health%20Organization%20Classification%20of%20Lung%20Tumors:%20impact%20of%20genetic,%20clinical%20and%20radiologic%20advances%20since%20the%202004%20classification.%20J.%20Thorac.%20Oncol.10,%201243%E2%80%931260%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Naidoo, J. et al. Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. <em>Clin. Lung Cancer</em><strong>17</strong>, e121–e129 (2016).
</cite> [<a href="https://doi.org/10.1016/j.cllc.2016.01.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5474315/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26898325/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Naidoo,%20J.%20et%20al.%20Large%20cell%20neuroendocrine%20carcinoma%20of%20the%20lung:%20clinico-pathologic%20features,%20treatment,%20and%20outcomes.%20Clin.%20Lung%20Cancer17,%20e121%E2%80%93e129%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Rekhtman, N. et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. <em>Clin. Cancer Res.</em><strong>22</strong>, 3618–3629 (2016).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-2946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4995776/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26960398/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rekhtman,%20N.%20et%20al.%20Next-generation%20sequencing%20of%20pulmonary%20large%20cell%20neuroendocrine%20carcinoma%20reveals%20small%20cell%20carcinoma-like%20and%20non-small%20cell%20carcinoma-like%20subsets.%20Clin.%20Cancer%20Res.22,%203618%E2%80%933629%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Jones, M. H. et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. <em>Lancet</em><strong>363</strong>, 775–781 (2004).
</cite> [<a href="https://doi.org/10.1016/S0140-6736(04)15693-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15016488/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jones,%20M.%20H.%20et%20al.%20Two%20prognostically%20significant%20subtypes%20of%20high-grade%20lung%20neuroendocrine%20tumours%20independent%20of%20small-cell%20and%20large-cell%20neuroendocrine%20carcinomas%20identified%20by%20gene%20expression%20profiles.%20Lancet363,%20775%E2%80%93781%20(2004)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Bari, M. F. et al. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas. <em>Histopathology</em><strong>64</strong>, 547–556 (2014).
</cite> [<a href="https://doi.org/10.1111/his.12278" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24266897/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bari,%20M.%20F.%20et%20al.%20BAI3,%20CDX2%20and%20VIL1:%20a%20panel%20of%20three%20antibodies%20to%20distinguish%20small%20cell%20from%20large%20cell%20neuroendocrine%20lung%20carcinomas.%20Histopathology64,%20547%E2%80%93556%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Simbolo, M. et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. <em>J. Pathol.</em><strong>241</strong>, 488–500 (2017).
</cite> [<a href="https://doi.org/10.1002/path.4853" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5324596/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27873319/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Simbolo,%20M.%20et%20al.%20Lung%20neuroendocrine%20tumours:%20deep%20sequencing%20of%20the%20four%20World%20Health%20Organization%20histotypes%20reveals%20chromatin-remodelling%20genes%20as%20major%20players%20and%20a%20prognostic%20role%20for%20TERT,%20RB1,%20MEN1%20and%20KMT2D.%20J.%20Pathol.241,%20488%E2%80%93500%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>De Pas, T. M. et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. <em>J. Clin. Oncol.</em><strong>29</strong>, e819–e822 (2011).
</cite> [<a href="https://doi.org/10.1200/JCO.2011.36.2251" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22042963/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?De%20Pas,%20T.%20M.%20et%20al.%20Large-cell%20neuroendocrine%20carcinoma%20of%20the%20lung%20harboring%20EGFR%20mutation%20and%20responding%20to%20gefitinib.%20J.%20Clin.%20Oncol.29,%20e819%E2%80%93e822%20(2011)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Aroldi, F. et al. Tyrosine kinase inhibitors in EGFR-mutated large-cell neuroendocrine carcinoma of the lung? A case report. <em>Case Rep. Oncol.</em><strong>7</strong>, 478–483 (2014).
</cite> [<a href="https://doi.org/10.1159/000365413" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4154195/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25202262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Aroldi,%20F.%20et%20al.%20Tyrosine%20kinase%20inhibitors%20in%20EGFR-mutated%20large-cell%20neuroendocrine%20carcinoma%20of%20the%20lung?%20A%20case%20report.%20Case%20Rep.%20Oncol.7,%20478%E2%80%93483%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Omachi, N. et al. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib. <em>J. Thorac. Oncol.</em><strong>9</strong>, e40–e42 (2014).
</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000103" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24828670/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Omachi,%20N.%20et%20al.%20A%20case%20of%20large-cell%20neuroendocrine%20carcinoma%20harboring%20an%20EML4-ALK%20rearrangement%20with%20resistance%20to%20the%20ALK%20inhibitor%20crizotinib.%20J.%20Thorac.%20Oncol.9,%20e40%E2%80%93e42%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Karlsson, A. et al. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. <em>Oncotarget</em><strong>6</strong>, 22028–22037 (2015).
</cite> [<a href="https://doi.org/10.18632/oncotarget.4314" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4673143/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26124082/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Karlsson,%20A.%20et%20al.%20Mutational%20and%20gene%20fusion%20analyses%20of%20primary%20large%20cell%20and%20large%20cell%20neuroendocrine%20lung%20cancer.%20Oncotarget6,%2022028%E2%80%9322037%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>George, J. et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <em>Nat. Commun.</em><strong>9</strong>, 1048 (2018).
</cite> [<a href="https://doi.org/10.1038/s41467-018-03099-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5849599/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29535388/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?George,%20J.%20et%20al.%20Integrative%20genomic%20profiling%20of%20large-cell%20neuroendocrine%20carcinomas%20reveals%20distinct%20subtypes%20of%20high-grade%20neuroendocrine%20lung%20tumors.%20Nat.%20Commun.9,%201048%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Derks, J. L. et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. <em>Clin. Cancer Res.</em><strong>24</strong>, 33–42 (2018).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-1921" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29066508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Derks,%20J.%20L.%20et%20al.%20Molecular%20subtypes%20of%20pulmonary%20large-cell%20neuroendocrine%20carcinoma%20predict%20chemotherapy%20treatment%20outcome.%20Clin.%20Cancer%20Res.24,%2033%E2%80%9342%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Miyoshi, T. et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. <em>Clin. Cancer Res.</em><strong>23</strong>, 757–765 (2017).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-16-0355" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27507618/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Miyoshi,%20T.%20et%20al.%20Genomic%20profiling%20of%20large-cell%20neuroendocrine%20carcinoma%20of%20the%20lung.%20Clin.%20Cancer%20Res.23,%20757%E2%80%93765%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Zhuo, M. et al. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. <em>Clin. Cancer Res.</em><strong>26</strong>, 892–901 (2020).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-0556" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7024651/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31694833/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhuo,%20M.%20et%20al.%20The%20prognostic%20and%20therapeutic%20role%20of%20genomic%20subtyping%20by%20sequencing%20tumor%20or%20cell-free%20DNA%20in%20pulmonary%20large-cell%20neuroendocrine%20carcinoma.%20Clin.%20Cancer%20Res.26,%20892%E2%80%93901%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. <em>N. Engl. J. Med.</em><strong>363</strong>, 711–723 (2010).
</cite> [<a href="https://doi.org/10.1056/NEJMoa1003466" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3549297/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20525992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hodi,%20F.%20S.%20et%20al.%20Improved%20survival%20with%20ipilimumab%20in%20patients%20with%20metastatic%20melanoma.%20N.%20Engl.%20J.%20Med.363,%20711%E2%80%93723%20(2010)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <em>Lancet Oncol.</em><strong>20</strong>, 1239–1251 (2019).
</cite> [<a href="https://doi.org/10.1016/S1470-2045(19)30388-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31345627/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Robert,%20C.%20et%20al.%20Pembrolizumab%20versus%20ipilimumab%20in%20advanced%20melanoma%20(KEYNOTE-006):%20post-hoc%205-year%20results%20from%20an%20open-label,%20multicentre,%20randomised,%20controlled,%20phase%203%20study.%20Lancet%20Oncol.20,%201239%E2%80%931251%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. <em>J. Clin. Oncol.</em><strong>38</strong>, 1–10 (2020).
</cite> [<a href="https://doi.org/10.1200/JCO.19.02105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8184060/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31682550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marabelle,%20A.%20et%20al.%20Efficacy%20of%20pembrolizumab%20in%20patients%20with%20noncolorectal%20high%20microsatellite%20instability/mismatch%20repair-deficient%20cancer:%20results%20from%20the%20phase%20II%20KEYNOTE-158%20study.%20J.%20Clin.%20Oncol.38,%201%E2%80%9310%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Andre, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. <em>N. Engl. J. Med.</em><strong>383</strong>, 2207–2218 (2020).
</cite> [<a href="https://doi.org/10.1056/NEJMoa2017699" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33264544/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Andre,%20T.%20et%20al.%20Pembrolizumab%20in%20microsatellite-instability-high%20advanced%20colorectal%20cancer.%20N.%20Engl.%20J.%20Med.383,%202207%E2%80%932218%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. <em>N. Engl. J. Med.</em><strong>373</strong>, 23–34 (2015).
</cite> [<a href="https://doi.org/10.1056/NEJMoa1504030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5698905/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26027431/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Larkin,%20J.%20et%20al.%20Combined%20nivolumab%20and%20ipilimumab%20or%20monotherapy%20in%20untreated%20melanoma.%20N.%20Engl.%20J.%20Med.373,%2023%E2%80%9334%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <em>Lancet</em><strong>394</strong>, 1915–1928 (2019).
</cite> [<a href="https://doi.org/10.1016/S0140-6736(19)32591-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31679945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Burtness,%20B.%20et%20al.%20Pembrolizumab%20alone%20or%20with%20chemotherapy%20versus%20cetuximab%20with%20chemotherapy%20for%20recurrent%20or%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20(KEYNOTE-048):%20a%20randomised,%20open-label,%20phase%203%20study.%20Lancet394,%201915%E2%80%931928%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. <em>N. Engl. J. Med.</em><strong>378</strong>, 2078–2092 (2018).
</cite> [<a href="https://doi.org/10.1056/NEJMoa1801005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29658856/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gandhi,%20L.%20et%20al.%20Pembrolizumab%20plus%20chemotherapy%20in%20metastatic%20non-small-cell%20lung%20cancer.%20N.%20Engl.%20J.%20Med.378,%202078%E2%80%932092%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Morris, V. K. et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <em>Lancet Oncol.</em><strong>18</strong>, 446–453 (2017).
</cite> [<a href="https://doi.org/10.1016/S1470-2045(17)30104-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5809128/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28223062/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Morris,%20V.%20K.%20et%20al.%20Nivolumab%20for%20previously%20treated%20unresectable%20metastatic%20anal%20cancer%20(NCI9673):%20a%20multicentre,%20single-arm,%20phase%202%20study.%20Lancet%20Oncol.18,%20446%E2%80%93453%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Wang, V. E. et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. <em>J. Immunother. Cancer</em><strong>5</strong>, 75 (2017).
</cite> [<a href="https://doi.org/10.1186/s40425-017-0281-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5604145/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28923100/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20V.%20E.%20et%20al.%20Checkpoint%20inhibitor%20is%20active%20against%20large%20cell%20neuroendocrine%20carcinoma%20with%20high%20tumor%20mutation%20burden.%20J.%20Immunother.%20Cancer5,%2075%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. <em>N. Engl. J. Med.</em><strong>375</strong>, 1823–1833 (2016).
</cite> [<a href="https://doi.org/10.1056/NEJMoa1606774" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27718847/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Reck,%20M.%20et%20al.%20Pembrolizumab%20versus%20chemotherapy%20for%20PD-L1-positive%20non-small-cell%20lung%20cancer.%20N.%20Engl.%20J.%20Med.375,%201823%E2%80%931833%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. <em>N. Engl. J. Med.</em><strong>379</strong>, 2220–2229 (2018).
</cite> [<a href="https://doi.org/10.1056/NEJMoa1809064" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30280641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Horn,%20L.%20et%20al.%20First-line%20atezolizumab%20plus%20chemotherapy%20in%20extensive-stage%20small-cell%20lung%20cancer.%20N.%20Engl.%20J.%20Med.379,%202220%E2%80%932229%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Paz-Ares, L. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. <em>ESMO Open</em><strong>7</strong>, 100408 (2022).
</cite> [<a href="https://doi.org/10.1016/j.esmoop.2022.100408" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9161394/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35279527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Paz-Ares,%20L.%20et%20al.%20Durvalumab,%20with%20or%20without%20tremelimumab,%20plus%20platinum-etoposide%20in%20first-line%20treatment%20of%20extensive-stage%20small-cell%20lung%20cancer:%203-year%20overall%20survival%20update%20from%20CASPIAN.%20ESMO%20Open7,%20100408%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Cheng, Y. et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. <em>N. Engl. J. Med.</em><strong>391</strong>, 1313–1327 (2024).
</cite> [<a href="https://doi.org/10.1056/NEJMoa2404873" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39268857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cheng,%20Y.%20et%20al.%20Durvalumab%20after%20chemoradiotherapy%20in%20limited-stage%20small-cell%20lung%20cancer.%20N.%20Engl.%20J.%20Med.391,%201313%E2%80%931327%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Mauclet, C. et al. Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab. <em>Lung Cancer</em><strong>128</strong>, 53–56 (2019).
</cite> [<a href="https://doi.org/10.1016/j.lungcan.2018.12.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30642453/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mauclet,%20C.%20et%20al.%20Complete%20tumor%20response%20of%20a%20locally%20advanced%20lung%20large-cell%20neuroendocrine%20carcinoma%20after%20palliative%20thoracic%20radiotherapy%20and%20immunotherapy%20with%20nivolumab.%20Lung%20Cancer128,%2053%E2%80%9356%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Zhang, X., Sun, Y., Miao, Y. &amp; Xu, S. Immune checkpoint inhibitor therapy achieved complete response for drug-sensitive EGFR/ALK mutation-negative metastatic pulmonary large-cell neuroendocrine carcinoma with high tumor mutation burden: a case report. <em>Onco Targets Ther.</em><strong>13</strong>, 8245–8250 (2020).
</cite> [<a href="https://doi.org/10.2147/OTT.S259893" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7443410/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32884302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang,%20X.,%20Sun,%20Y.,%20Miao,%20Y.%20&amp;%20Xu,%20S.%20Immune%20checkpoint%20inhibitor%20therapy%20achieved%20complete%20response%20for%20drug-sensitive%20EGFR/ALK%20mutation-negative%20metastatic%20pulmonary%20large-cell%20neuroendocrine%20carcinoma%20with%20high%20tumor%20mutation%20burden:%20a%20case%20report.%20Onco%20Targets%20Ther.13,%208245%E2%80%938250%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Oda, R. et al. Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab. <em>Thorac. Cancer</em><strong>11</strong>, 2036–2039 (2020).
</cite> [<a href="https://doi.org/10.1111/1759-7714.13471" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7327674/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32379390/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oda,%20R.%20et%20al.%20Long-term%20survivor%20of%20pulmonary%20combined%20large%20cell%20neuroendocrine%20carcinoma%20treated%20with%20nivolumab.%20Thorac.%20Cancer11,%202036%E2%80%932039%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Sherman, S. et al. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). <em>Lung Cancer</em><strong>143</strong>, 40–46 (2020).
</cite> [<a href="https://doi.org/10.1016/j.lungcan.2020.03.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32203769/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sherman,%20S.%20et%20al.%20Efficacy%20of%20immune%20check-point%20inhibitors%20(ICPi)%20in%20large%20cell%20neuroendocrine%20tumors%20of%20lung%20(LCNEC).%20Lung%20Cancer143,%2040%E2%80%9346%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Dudnik, E. et al. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. <em>J. Immunother. Cancer</em><strong>9</strong>, 10.1136/jitc-2020-001999 (2021).</cite> [<a href="https://doi.org/10.1136/jitc-2020-001999" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7893659/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33597218/" class="usa-link">PubMed</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Owen, D. H. et al. A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms. <em>Clin. Cancer Res.</em><strong>29</strong>, 731–741 (2023).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-1552" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9932582/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36255391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Owen,%20D.%20H.%20et%20al.%20A%20phase%20II%20clinical%20trial%20of%20nivolumab%20and%20temozolomide%20for%20neuroendocrine%20neoplasms.%20Clin.%20Cancer%20Res.29,%20731%E2%80%93741%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Chen, H. Z. et al. Genomic and transcriptomic characterization of relapsed SCLC through rapid research autopsy. <em>JTO Clin. Res Rep.</em><strong>2</strong>, 100164 (2021).
</cite> [<a href="https://doi.org/10.1016/j.jtocrr.2021.100164" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8474405/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34590014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen,%20H.%20Z.%20et%20al.%20Genomic%20and%20transcriptomic%20characterization%20of%20relapsed%20SCLC%20through%20rapid%20research%20autopsy.%20JTO%20Clin.%20Res%20Rep.2,%20100164%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Rudin, C. M. et al. Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <em>Nat. Rev. Cancer</em><strong>19</strong>, 415 (2019).
</cite> [<a href="https://doi.org/10.1038/s41568-019-0164-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31175338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rudin,%20C.%20M.%20et%20al.%20Author%20Correction:%20Molecular%20subtypes%20of%20small%20cell%20lung%20cancer:%20a%20synthesis%20of%20human%20and%20mouse%20model%20data.%20Nat.%20Rev.%20Cancer19,%20415%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Owonikoko, T. K. et al. YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype. <em>J. Thorac. Oncol.</em><strong>16</strong>, 464–476 (2021).
</cite> [<a href="https://doi.org/10.1016/j.jtho.2020.11.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7920957/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33248321/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Owonikoko,%20T.%20K.%20et%20al.%20YAP1%20expression%20in%20SCLC%20defines%20a%20distinct%20subtype%20with%20T-cell-inflamed%20phenotype.%20J.%20Thorac.%20Oncol.16,%20464%E2%80%93476%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Wang, J. et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. <em>Cell</em><strong>176</strong>, 334–347.e12 (2019).
</cite> [<a href="https://doi.org/10.1016/j.cell.2018.11.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6365968/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30580966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20J.%20et%20al.%20Fibrinogen-like%20protein%201%20is%20a%20major%20immune%20inhibitory%20ligand%20of%20LAG-3.%20Cell176,%20334%E2%80%93347.e12%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Cancer Genome Atlas Research Network Author Correction: Comprehensive molecular profiling of lung adenocarcinoma. <em>Nature</em><strong>559</strong>, E12 (2018).
</cite> [<a href="https://doi.org/10.1038/s41586-018-0228-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29925941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cancer%20Genome%20Atlas%20Research%20Network%20Author%20Correction:%20Comprehensive%20molecular%20profiling%20of%20lung%20adenocarcinoma.%20Nature559,%20E12%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Ateeq, B. et al. Therapeutic targeting of SPINK1-positive prostate cancer. <em>Sci. Transl. Med.</em><strong>3</strong>, 72ra17 (2011).
</cite> [<a href="https://doi.org/10.1126/scitranslmed.3001498" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3211047/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21368222/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ateeq,%20B.%20et%20al.%20Therapeutic%20targeting%20of%20SPINK1-positive%20prostate%20cancer.%20Sci.%20Transl.%20Med.3,%2072ra17%20(2011)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Chen, F. et al. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. <em>Nat. Commun.</em><strong>9</strong>, 4315 (2018).
</cite> [<a href="https://doi.org/10.1038/s41467-018-06860-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6193001/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30333494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen,%20F.%20et%20al.%20Targeting%20SPINK1%20in%20the%20damaged%20tumour%20microenvironment%20alleviates%20therapeutic%20resistance.%20Nat.%20Commun.9,%204315%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. <em>Cell Syst.</em><strong>1</strong>, 417–425 (2015).
</cite> [<a href="https://doi.org/10.1016/j.cels.2015.12.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4707969/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26771021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liberzon,%20A.%20et%20al.%20The%20Molecular%20Signatures%20Database%20(MSigDB)%20hallmark%20gene%20set%20collection.%20Cell%20Syst.1,%20417%E2%80%93425%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Wei, S. C., Duffy, C. R. &amp; Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. <em>Cancer Discov.</em><strong>8</strong>, 1069–1086 (2018).
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-18-0367" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30115704/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wei,%20S.%20C.,%20Duffy,%20C.%20R.%20&amp;%20Allison,%20J.%20P.%20Fundamental%20mechanisms%20of%20immune%20checkpoint%20blockade%20therapy.%20Cancer%20Discov.8,%201069%E2%80%931086%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Rakaee, M. et al. Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC. <em>JAMA Oncol.</em><strong>9</strong>, 51–60 (2023).
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2022.4933" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9673028/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36394839/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rakaee,%20M.%20et%20al.%20Association%20of%20machine%20learning-based%20assessment%20of%20tumor-infiltrating%20lymphocytes%20on%20standard%20histologic%20images%20with%20outcomes%20of%20immunotherapy%20in%20patients%20with%20NSCLC.%20JAMA%20Oncol.9,%2051%E2%80%9360%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Agar, C. et al. Brief report on the efficacy of nivolumab in patients with previously treated advanced large-cell neuroendocrine cancer of the lung. <em>JTO Clin. Res. Rep.</em><strong>2</strong>, 100129 (2021).
</cite> [<a href="https://doi.org/10.1016/j.jtocrr.2020.100129" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8474479/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34590004/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Agar,%20C.%20et%20al.%20Brief%20report%20on%20the%20efficacy%20of%20nivolumab%20in%20patients%20with%20previously%20treated%20advanced%20large-cell%20neuroendocrine%20cancer%20of%20the%20lung.%20JTO%20Clin.%20Res.%20Rep.2,%20100129%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Ozaki, N. et al. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. <em>Mol. Cancer Res.</em><strong>7</strong>, 1572–1581 (2009).
</cite> [<a href="https://doi.org/10.1158/1541-7786.MCR-08-0567" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19737965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ozaki,%20N.%20et%20al.%20Serine%20protease%20inhibitor%20Kazal%20type%201%20promotes%20proliferation%20of%20pancreatic%20cancer%20cells%20through%20the%20epidermal%20growth%20factor%20receptor.%20Mol.%20Cancer%20Res.7,%201572%E2%80%931581%20(2009)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Wang, C. et al. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer. <em>Prostate</em><strong>74</strong>, 689–701 (2014).
</cite> [<a href="https://doi.org/10.1002/pros.22787" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24619958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20C.%20et%20al.%20Serine%20protease%20inhibitor%20Kazal%20type%201%20promotes%20epithelial-mesenchymal%20transition%20through%20EGFR%20signaling%20pathway%20in%20prostate%20cancer.%20Prostate74,%20689%E2%80%93701%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Tiwari, R. et al. Correction: SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. <em>Oncogenesis</em><strong>10</strong>, 16 (2021).
</cite> [<a href="https://doi.org/10.1038/s41389-021-00305-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7900126/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33619267/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tiwari,%20R.%20et%20al.%20Correction:%20SPINK1%20promotes%20colorectal%20cancer%20progression%20by%20downregulating%20Metallothioneins%20expression.%20Oncogenesis10,%2016%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Marchbank, T., Mahmood, A. &amp; Playford, R. J. Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. <em>Am. J. Physiol. Ren. Physiol.</em><strong>305</strong>, F382–F389 (2013).</cite> [<a href="https://doi.org/10.1152/ajprenal.00357.2012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23698120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marchbank,%20T.,%20Mahmood,%20A.%20&amp;%20Playford,%20R.%20J.%20Pancreatic%20secretory%20trypsin%20inhibitor%20causes%20autocrine-mediated%20migration%20and%20invasion%20in%20bladder%20cancer%20and%20phosphorylates%20the%20EGF%20receptor,%20Akt2%20and%20Akt3,%20and%20ERK1%20and%20ERK2.%20Am.%20J.%20Physiol.%20Ren.%20Physiol.305,%20F382%E2%80%93F389%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Ahn, M. J. et al. Tarlatamab for patients with previously treated small-cell lung cancer. <em>N. Engl. J. Med.</em><strong>389</strong>, 2063–2075 (2023).
</cite> [<a href="https://doi.org/10.1056/NEJMoa2307980" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37861218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ahn,%20M.%20J.%20et%20al.%20Tarlatamab%20for%20patients%20with%20previously%20treated%20small-cell%20lung%20cancer.%20N.%20Engl.%20J.%20Med.389,%202063%E2%80%932075%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Baine, M. K. et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. <em>J. Thorac. Oncol.</em><strong>15</strong>, 1823–1835 (2020).
</cite> [<a href="https://doi.org/10.1016/j.jtho.2020.09.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8362797/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33011388/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Baine,%20M.%20K.%20et%20al.%20SCLC%20subtypes%20defined%20by%20ASCL1,%20NEUROD1,%20POU2F3,%20and%20YAP1:%20a%20comprehensive%20immunohistochemical%20and%20histopathologic%20characterization.%20J.%20Thorac.%20Oncol.15,%201823%E2%80%931835%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Ng, J. et al. Molecular and pathologic characterization of YAP1-expressing small cell lung cancer cell lines leads to reclassification as SMARCA4-deficient malignancies. <em>Clin. Cancer Res.</em><strong>30</strong>, 1846–1858 (2024).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-23-2360" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11061608/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38180245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ng,%20J.%20et%20al.%20Molecular%20and%20pathologic%20characterization%20of%20YAP1-expressing%20small%20cell%20lung%20cancer%20cell%20lines%20leads%20to%20reclassification%20as%20SMARCA4-deficient%20malignancies.%20Clin.%20Cancer%20Res.30,%201846%E2%80%931858%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Stewart, C. A. et al. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities. <em>Clin. Cancer Res.</em><strong>30</strong>, 4743–4754 (2024).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-24-0361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11479841/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39150543/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Stewart,%20C.%20A.%20et%20al.%20YAP1%20status%20defines%20two%20intrinsic%20subtypes%20of%20LCNEC%20with%20distinct%20molecular%20features%20and%20therapeutic%20vulnerabilities.%20Clin.%20Cancer%20Res.30,%204743%E2%80%934754%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Rindi, G. et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. <em>Endocr. Pathol.</em><strong>33</strong>, 115–154 (2022).
</cite> [<a href="https://doi.org/10.1007/s12022-022-09708-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35294740/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rindi,%20G.%20et%20al.%20Overview%20of%20the%202022%20WHO%20Classification%20of%20Neuroendocrine%20Neoplasms.%20Endocr.%20Pathol.33,%20115%E2%80%93154%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Muquith, M. et al. Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. <em>Nat. Cancer</em>10.1038/s43018-024-00752-x (2024).</cite> [<a href="https://doi.org/10.1038/s43018-024-00752-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38528112/" class="usa-link">PubMed</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. <em>JCO Precis. Oncol.</em><strong>2017</strong>, 10.1200/PO.17.00011 (2017).</cite> [<a href="https://doi.org/10.1200/PO.17.00011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5586540/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28890946/" class="usa-link">PubMed</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Suehnholz, S. P. et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. <em>Cancer Discov.</em><strong>14</strong>, 49–65 (2024).
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-23-0467" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10784742/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37849038/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Suehnholz,%20S.%20P.%20et%20al.%20Quantifying%20the%20expanding%20landscape%20of%20clinical%20actionability%20for%20patients%20with%20cancer.%20Cancer%20Discov.14,%2049%E2%80%9365%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Richards, S. et al. Committee ALQA. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <em>Genet. Med.</em><strong>17</strong>, 405–424 (2015).
</cite> [<a href="https://doi.org/10.1038/gim.2015.30" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4544753/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25741868/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Richards,%20S.%20et%20al.%20Committee%20ALQA.%20Standards%20and%20guidelines%20for%20the%20interpretation%20of%20sequence%20variants:%20a%20joint%20consensus%20recommendation%20of%20the%20American%20College%20of%20Medical%20Genetics%20and%20Genomics%20and%20the%20Association%20for%20Molecular%20Pathology.%20Genet.%20Med.17,%20405%E2%80%93424%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. &amp; Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. <em>Nat. Methods</em><strong>14</strong>, 417–419 (2017).
</cite> [<a href="https://doi.org/10.1038/nmeth.4197" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5600148/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28263959/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Patro,%20R.,%20Duggal,%20G.,%20Love,%20M.%20I.,%20Irizarry,%20R.%20A.%20&amp;%20Kingsford,%20C.%20Salmon%20provides%20fast%20and%20bias-aware%20quantification%20of%20transcript%20expression.%20Nat.%20Methods14,%20417%E2%80%93419%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Finotello, F. et al. Correction to: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. <em>Genome Med.</em><strong>11</strong>, 50 (2019).
</cite> [<a href="https://doi.org/10.1186/s13073-019-0655-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6661746/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31358023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Finotello,%20F.%20et%20al.%20Correction%20to:%20Molecular%20and%20pharmacological%20modulators%20of%20the%20tumor%20immune%20contexture%20revealed%20by%20deconvolution%20of%20RNA-seq%20data.%20Genome%20Med.11,%2050%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Kim, S. Y. et al. Characterization of MET Exon 14 skipping alterations (in NSCLC) and identification of potential therapeutic targets using whole transcriptome sequencing. <em>JTO Clin. Res Rep.</em><strong>3</strong>, 100381 (2022).
</cite> [<a href="https://doi.org/10.1016/j.jtocrr.2022.100381" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9445394/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36082279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim,%20S.%20Y.%20et%20al.%20Characterization%20of%20MET%20Exon%2014%20skipping%20alterations%20(in%20NSCLC)%20and%20identification%20of%20potential%20therapeutic%20targets%20using%20whole%20transcriptome%20sequencing.%20JTO%20Clin.%20Res%20Rep.3,%20100381%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Wang, J. et al. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. <em>Lancet Oncol.</em><strong>24</strong>, 151–161 (2023).
</cite> [<a href="https://doi.org/10.1016/S1470-2045(22)00783-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10599647/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36681091/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20J.%20et%20al.%20Mutational%20analysis%20of%20microsatellite-stable%20gastrointestinal%20cancer%20with%20high%20tumour%20mutational%20burden:%20a%20retrospective%20cohort%20study.%20Lancet%20Oncol.24,%20151%E2%80%93161%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <em>Lancet Oncol.</em><strong>21</strong>, 1353–1365 (2020).
</cite> [<a href="https://doi.org/10.1016/S1470-2045(20)30445-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32919526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marabelle,%20A.%20et%20al.%20Association%20of%20tumour%20mutational%20burden%20with%20outcomes%20in%20patients%20with%20advanced%20solid%20tumours%20treated%20with%20pembrolizumab:%20prospective%20biomarker%20analysis%20of%20the%20multicohort,%20open-label,%20phase%202%20KEYNOTE-158%20study.%20Lancet%20Oncol.21,%201353%E2%80%931365%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supplementary information</a><sup> (2.1MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM2_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Peer review</a><sup> (65.1KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM3_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Reporting Summary</a><sup> (101.6KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM4_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">41467_2025_63091_MOESM4_ESM.pdf</a><sup> (6.3KB, pdf) </sup><p>Description of Additional Supplementary Files</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM5_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Data 1–8</a><sup> (4.9MB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material6_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12365225/bin/41467_2025_63091_MOESM6_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Source data</a><sup> (119.8MB, xlsx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Raw sequencing data for Figs. <a href="#Fig1" class="usa-link">1b</a>, <a href="#Fig2" class="usa-link">2b–e</a>, <a href="#Fig3" class="usa-link">3</a>, <a href="#Fig4" class="usa-link">4</a> and <a href="#Fig5" class="usa-link">5a, b</a> were generated by Caris Life Sciences and are not publicly available due to patient privacy concerns and proprietary restrictions. These data are considered third-party clinical datasets and are owned by Caris Life Sciences. Access is restricted due to legal and privacy protections. Raw data cannot be deposited in a public repository. Aggregated and de-identified data may be made available for academic research purposes upon request. Researchers should contact the corresponding author with a brief description of the data required and the intended use. All requests will be reviewed by the Caris data access team, and a response will be provided within 4 weeks. Once access is granted, data will remain available for the duration of the agreed-upon research project, subject to compliance with Caris Life Sciences’ data use agreement. External datasets used in this study are publicly available<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>,<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a></sup>. All other data supporting the findings of this study, including source data underlying the figures and tables (excluding the Caris-derived panels), are provided in the accompanying Source data file. <a href="#Sec23" class="usa-link">Source data</a> are provided with this paper.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Nature Communications are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41467-025-63091-0"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41467_2025_Article_63091.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.6 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12365225/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12365225/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365225%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365225/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12365225/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12365225/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830141/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12365225/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830141/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12365225/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12365225/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="GQBbrLHm8zyVSjZsxFUxo2jBSRawtaOwVvEpw97bBKe6e5om2zKoZmY9advvwK1M">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
